#BCSM Transcript
Healthcare social media transcript of the #BCSM hashtag.
– ().
See #BCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | NCI Cancer Stats @NCICancerStats Black women are more likely than women of other races/ethnicities to die from breast #cancer. Learn more about this disease here: https://t.co/OWYkgGZP9a #BCSM https://t.co/2TwMfZcJQJ |
 | Dr. Steffi Oesterreich @oesterreichs @StoverLab Great you can join us! #bcsm |
 | Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey Read this RIGHT TF NOW. And then hop on the #bcsm chat at 9pm ET. https://t.co/O4TADy8wlf HT @double_whammied |
 | Dr. Susan Love @DrSusanLove RT @tmprowell: Lumpectomy + RT for #DCIS assoc w/ better 15 yr #BreastCancer mortality than lump or MRM alone. Note that in absolute terms we’re talking a diff of ~0.5%. #bcsm h/t @DrSGraff https://t.co/EP4ZVeDHSm https://t.co/7fxBTqd6rw |
 | Adrian Lee @Adrianvlee What are the key questions key to address in lobular cancer? Detection? Treatment? Prevention recurrence? #BCSM |
 | Double Whammy @double_whammied RT @MightyCasey: Read this RIGHT TF NOW. And then hop on the #bcsm chat at 9pm ET. https://t.co/O4TADy8wlf HT @double_whammied |
 | Alicia C. Staley @stales Alright, it's 9 pm ET. Good evening #BCSM crew! |
| Double Whammy @double_whammied Woo hoo! #BCSM on #ILC is up and running |
 | Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins Hi #bcsm and #lobmob! Becca from @LombardiCancer, #lobular breast cancer researcher |
| Alicia C. Staley @stales @Jpete008 hi there! #bcsm |
| Alicia C. Staley @stales @Prof_Riggins @LombardiCancer Welcome! Nice to see you! #bcsm |
| Alicia C. Staley @stales @double_whammied Hello, hello! #bcsm |
| Alicia C. Staley @stales @MightyCasey @double_whammied bingo! #bcsm |
| Double Whammy @double_whammied So glad you could join us tonight, Dr. Attai! #BCSM |
 | Julie Gralow @jrgralow Hi Everyone. Julie Gralow here - breast med onc from Seattle #bcsm |
| Alicia C. Staley @stales @oesterreichs @StoverLab Welcome! #bcsm |
| Alicia C. Staley @stales @StoverLab Welcome! #bcsm |
 | Howard Karpoff @doctorkarpoff RT @stales: Alright, it's 9 pm ET. Good evening #BCSM crew! |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey Here for a bit. 9pm ET = not my finest hour, brain wise. I'm plant life. #BCSM |
 | Hello_U👋🏼 @MommysCancer RT @stales: Alright, it's 9 pm ET. Good evening #BCSM crew! |
 | Dr. Deanna Attai @DrAttai #bcsm - recommend putting the hashtag B4 tweet if tweet >140. Otherwise won't show up on platforms like https://t.co/XtlQJVHkF1 |
 | Lobular Research @LobularResearch What biomarkers have been identified, if any, from the Pitt Endocrine Response clinical trial (NCT02206984)? #bcsm #lobular #ILC #breastcancer |
 | Gary L. Thompson @garyleethompson Greetings #bcsm friends. Checking in as myself tonight and not @CLOUDHealth When discussing #breastcancer from personal perspective, not CLOUD work on new data paradigm, I want to be "me!" :-) |
| Alicia C. Staley @stales Good evening! Please take a moment to say hello. We will get started shortly #bcsm |
| Alicia C. Staley @stales @garyleethompson @CLOUDHealth hello! #bcsm |
 | Matthew J. Sikora, PhD @mjsikora Hello BCSM! Matt - scientist and lobular researcher from Colorado. Long time BCSM lurker. #bcsm |
 | Rod Ritchie @malefitness BCa 2014 and PCa 2016. NED for both. #bcsm |
 | Dennis Keim @denniskeim Howdy, #bcsm peeps. Stage 1 breast cancer dx in 2013. Still NED (No Evidence of Disease) in NE. |
| Alicia C. Staley @stales @MightyCasey :-) Cheers! #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @LobularResearch: What biomarkers have been identified, if any, from the Pitt Endocrine Response clinical trial (NCT02206984)? #bcsm #lobular #ILC #breastcancer |
| Alicia C. Staley @stales @denniskeim hi Dennis! Great to see you. #bcsm |
| Alicia C. Staley @stales @malefitness hello!! #bcsm |
| Dr. Steffi Oesterreich @oesterreichs @Adrianvlee Understanding imaging is very important, also we need to understand differences in basic biology so we can personalize medicine #bcsm |
| Double Whammy @double_whammied Diane Mapes here from Seattle, Dx'd with #lobular #breastcancer in Feb 2011. Trying to get the word out about this freaky sneaky subtype of #BC. #BCSM |
| Alicia C. Staley @stales @mjsikora Wow, welcome! Thanks for joining in tonight. #bcsm |
 | Katherine OBrien @ihatebreastcanc @Adrianvlee #BCSM how about acknowledgement? was at patient seminar with Lobular Mets patients and they were told treatment is the same as for IDC. Not exactly a font of information! patients must push for answers because there isn’t a lot offered...for most |
| Alicia C. Staley @stales @fckboobiecancer whoop whoop #bcsm |
 | Lobular Breast Cancer Alliance @LobularBCA Hello from the @lobularbca Lobular Breast Cancer Alliance! https://t.co/leLzt5mvu5 #lobmob #lobular #ILC #bcsm |
| Katherine OBrien @ihatebreastcanc RT @LobularResearch: What biomarkers have been identified, if any, from the Pitt Endocrine Response clinical trial (NCT02206984)? #bcsm #lobular #ILC #breastcancer |
| Julie Gralow @jrgralow RT @double_whammied: Diane Mapes here from Seattle, Dx'd with #lobular #breastcancer in Feb 2011. Trying to get the word out about this freaky sneaky subtype of #BC. #BCSM |
| Alicia C. Staley @stales We will get started with the questions in a moment. #bcsm |
 | ProprioStrength @ProprioStrength Howdy, Cheryl from Seattle here. Working toward lobular advocacy. #bcsm |
 | Dr. Kelly Shanahan @stage4kelly Kelly, former ob/gyn and current MBC patient, checking in from mildly smoky Lake Tahoe. Tired tonight as I didn’t get much sleep because my baby was flying to Europe all by herself yesterday. Grateful that she kept me updated thru flights and trains #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA RT @oesterreichs: @Adrianvlee Understanding imaging is very important, also we need to understand differences in basic biology so we can personalize medicine #bcsm |
| Katherine OBrien @ihatebreastcanc RT @jrgralow: Hi Everyone. Julie Gralow here - breast med onc from Seattle #bcsm |
| Alicia C. Staley @stales As a reminder, you can learn more about the #BCSM community here: https://t.co/rUD9nLTZe4 |
| Double Whammy @double_whammied @stage4kelly So glad you could make it, Kelly! #BCSM #lobularbc |
| Katherine OBrien @ihatebreastcanc RT @oesterreichs: @Adrianvlee Understanding imaging is very important, also we need to understand differences in basic biology so we can personalize medicine #bcsm |
| Katherine OBrien @ihatebreastcanc RT @garyleethompson: Greetings #bcsm friends. Checking in as myself tonight and not @CLOUDHealth When discussing #breastcancer from personal perspective, not CLOUD work on new data paradigm, I want to be "me!" :-) |
| Katherine OBrien @ihatebreastcanc RT @double_whammied: Diane Mapes here from Seattle, Dx'd with #lobular #breastcancer in Feb 2011. Trying to get the word out about this freaky sneaky subtype of #BC. #BCSM |
| Double Whammy @double_whammied RT @stales: We will get started with the questions in a moment. #bcsm |
 | Hillary (Stires) Andrews, PhD @HillStirSci @stales Hi all!! I'm Hillary, a postdoc at @LombardiCancer studying endocrine resistance in #lobular, coming off of a great weekend celebrating my BFFs 30th birthday - her first since diagnosis that she's celebrated NED! #bcsm |
 | Mia Spano-Curtiss & Sondra Price @BSBreastCancer RT @stales: @fckboobiecancer whoop whoop #bcsm |
| Alicia C. Staley @stales You can also learn more about the tweet chat here: https://t.co/0KzBtOpPgz #bcsm |
| Dennis Keim @denniskeim RT @stales: As a reminder, you can learn more about the #BCSM community here: As a reminder, you can learn more about the #BCSM community here: https://t.co/rUD9nLTZe4 |
| Alicia C. Staley @stales @HillStirSci @LombardiCancer hey there! Nice to see you! #bcsm |
| Gary L. Thompson @garyleethompson @stage4kelly My sister and family from Charlotte, NC just spent the last few days there in South Lake Tahoe... they had to cancel time in Yosemite. Hope all stay safe out there!! #bcsm |
| Alicia C. Staley @stales @stage4kelly hey! hugs! #bcsm |
| Alicia C. Staley @stales @ProprioStrength Welcome! #bcsm |
| Double Whammy @double_whammied @TalkIBC Awesome! GLad you could make it, Terry! #BCSM |
| Katherine OBrien @ihatebreastcanc Hi #bcsm it’s Katherine living with Mets since 2009. not Lobular but as a patient advocate I want to learn and share |
| Dennis Keim @denniskeim RT @oesterreichs: Join us for a discussion on ILC tonight 9pm EST. #bcsm |
 | The IBC Network Foundation @TalkIBC All cancer sucks but really sucks to have to explain it all the time, right? "You have what...? " #bcsm |
| Elizabeth Viggiano @EV11PDX de novo stage 4 in 2015... #bcsm |
| Double Whammy @double_whammied RT @ihatebreastcanc: @Adrianvlee #BCSM how about acknowledgement? was at patient seminar with Lobular Mets patients and they were told treatment is the same as for IDC. Not exactly a font of information! patients must push for answers because there isn’t a lot offered...for most |
| Alicia C. Staley @stales Tonight, we are talking about lobular Breast Cancer - more on the #bcsm site: https://t.co/khmTAmywyF |
| Dr. Kelly Shanahan @stage4kelly @garyleethompson The fires are over 100 miles away, but the smoke travels far. #bcsm |
| Katherine OBrien @ihatebreastcanc RT @ProprioStrength: Howdy, Cheryl from Seattle here. Working toward lobular advocacy. #bcsm |
| Double Whammy @double_whammied Thanks for the shoutout, @DrAttai. #BCSM |
| Alicia C. Staley @stales Please welcome our special guests for tonight's chat: @double_whammied @oesterreichs @LobularBCA @jrgralow #bcsm |
| Dr. Deanna Attai @DrAttai @stage4kelly @garyleethompson #bcsm I'm in LA and there was ash on the ground the other morning |
| Alicia C. Staley @stales T1 is coming up! #bcsm |
 | Lex @Lex_in_CO Checking in from N Colorado. Patient dx Stage IV de novo 5 yrs ago #BCSM |
| Alicia C. Staley @stales @DrAttai @stage4kelly @garyleethompson WHAT! are you serious? that's awful #bcsm |
 | SouthrnBeachGrl @SouthrnBeachGrl RT @LobularBCA: Join lobular breast cancer patients and @LobularBCA on a #BCSM (breast cancer social media) tweetchat. Monday, Aug 13, at 9 p.m. EST #bcsm #lobular #breastcancer https://t.co/wfbx0t83w3 |
| Double Whammy @double_whammied RT @stales: Please welcome our special guests for tonight's chat: Please welcome our special guests for tonight's chat: @double_whammied @oesterreichs @LobularBCA @jrgralow #bcsm |
| Dr. Deanna Attai @DrAttai @stales @stage4kelly @garyleethompson #bcsm Cali fires this summer are no joke. So many lives lost or destroyed. Just devastating |
| Katherine OBrien @ihatebreastcanc RT @stales: Please welcome our special guests for tonight's chat: Please welcome our special guests for tonight's chat: @double_whammied @oesterreichs @LobularBCA @jrgralow #bcsm |
| Katherine OBrien @ihatebreastcanc RT @Lex_in_CO: Checking in from N Colorado. Patient dx Stage IV de novo 5 yrs ago #BCSM |
| Dr. Steffi Oesterreich @oesterreichs @ihatebreastcanc @Adrianvlee #bcsm We know that there are differences between metastasis in IDC and ILC, but don't know the underlying biology yet. We need more research on ILC to find specific information and targets |
| Adrian Lee @Adrianvlee Nice clinical review on ILC https://t.co/1M57BSLsnh #BCSM |
| Alicia C. Staley @stales @ndenduluri1 Welcome! #bcsm |
 | Leslie @Leslieks Greetings #bcsm friends. |
| Dennis Keim @denniskeim RT @double_whammied: Diane Mapes here from Seattle, Dx'd with #lobular #breastcancer in Feb 2011. Trying to get the word out about this freaky sneaky subtype of #BC. #BCSM |
| Katherine OBrien @ihatebreastcanc RT @oesterreichs: @ihatebreastcanc @Adrianvlee #bcsm We know that there are differences between metastasis in IDC and ILC, but don't know the underlying biology yet. We need more research on ILC to find specific information and targets |
| Alicia C. Staley @stales T1: @double_whammied @oesterreichs @LobularBCA @jrgralow -- What is Lobular Breast Cancer? What do we need to know? #bcsm |
| Alicia C. Staley @stales @Leslieks Welcome! #bcsm |
| Hillary (Stires) Andrews, PhD @HillStirSci @itsthebunk Hi Liza! #bcsm |
| Julie Gralow @jrgralow Lots of lobular breast cancer patients on this chat! #bcsm |
| Julie Gralow @jrgralow RT @jrgralow: And here's another link to an invasive lobular piece also written by @double_whammied for @fredhutch #bcsm https://t.co/vOFv1662DD https://t.co/cYfyjhh455 |
 | IBC Research Fdn @IBCResearch Hi...#IBCer Dx 1994, TN, also an RN. 24/7 advocacy work. Catching up after 2 1/2 wk away doing cancer related stuff #BCSM |
| mary smith @ggmanonie RT @stales: @Leslieks Welcome! #bcsm |
| Dennis Keim @denniskeim @itsthebunk Hey, Liza! :) #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @jrgralow: RT @jrgralow: RT @jrgralow: And here's another link to an invasive lobular piece also written by @double_whammied for @fredhutch #bcsm https://t.co/vOFv1662DD https://t.co/cYfyjhh455 |
| Matthew J. Sikora, PhD @mjsikora RT @Adrianvlee: Nice clinical review on ILC https://t.co/1M57BSLsnh #BCSM |
| Alicia C. Staley @stales @jrgralow Yes, happy to see some new faces that want to learn more. Thank you for participating tonight! #bcsm |
| Alicia C. Staley @stales @akknowles1 good luck! #bcsm |
| Alicia C. Staley @stales RT @Adrianvlee Nice clinical review on ILC https://t.co/HoarqSCtTb #BCSM |
| Dr. Steffi Oesterreich @oesterreichs @stales @double_whammied @LobularBCA @jrgralow It is the second most common histologic subtype of breast cancer, representing 10-15% of all diagnosed breast cancers #BCSM |
| Alicia C. Staley @stales @Lex_in_CO hope you are doing well! #bcsm |
| Double Whammy @double_whammied T1: #ILC #lobular #BC often doesn't make a lump. I had a "dent" or "tuck" in my breast. NO LUMP! #BCSM |
| The IBC Network Foundation @TalkIBC RT @oesterreichs: @stales @double_whammied @LobularBCA @jrgralow It is the second most common histologic subtype of breast cancer, representing 10-15% of all diagnosed breast cancers #BCSM |
| Alicia C. Staley @stales RT @double_whammied T1: #ILC #lobular #BC often doesn't make a lump. I had a "dent" or "tuck" in my breast. NO LUMP! #BCSM |
| Dennis Keim @denniskeim RT @stales: RT @double_whammied T1: RT @double_whammied T1: #ILC #lobular #BC often doesn't make a lump. I had a "dent" or "tuck" in my breast. NO LUMP! #BCSM |
| Matthew J. Sikora, PhD @mjsikora RT @double_whammied: T1: T1: #ILC #lobular #BC often doesn't make a lump. I had a "dent" or "tuck" in my breast. NO LUMP! #BCSM |
| Julie Gralow @jrgralow T1: Invasive lobular carcinoma comprises about 10-15% of breast cancers. Doesn't make a lump, so difficult to find on imaging and physical exam! Most patients report a thickening, or subtle difference between the two breasts. #bcsm |
| Katherine OBrien @ihatebreastcanc Different metastatic sites? #bcsm |
| Dr. Kelly Shanahan @stage4kelly @DrAttai @garyleethompson Probably from the Holy fire, in orange county. My daughter lives in orange, although right now she’s across the pond in Austria #bcsm |
| Alicia C. Staley @stales RT @jrgralow T1: Invasive lobular carcinoma comprises about 10-15% of breast cancers. Doesn't make a lump, difficult to find #bcsm |
| Dr. Susan Love @DrSusanLove RT @jrgralow: T1: T1: Invasive lobular carcinoma comprises about 10-15% of breast cancers. Doesn't make a lump, so difficult to find on imaging and physical exam! Most patients report a thickening, or subtle difference between the two breasts. #bcsm |
| Julie Gralow @jrgralow RT @double_whammied: T1: T1: #ILC #lobular #BC often doesn't make a lump. I had a "dent" or "tuck" in my breast. NO LUMP! #BCSM |
| Dr. Steffi Oesterreich @oesterreichs @stales @double_whammied @LobularBCA @jrgralow #bcsm The main difference is that the cells lack e-cadherin, which glues cells together. As a result, the tumor cells grow in a spider-web like fashion and not as a lump |
| Dr. Deanna Attai @DrAttai @stales @double_whammied #bcsm T1 "dent", "dimple" etc can also be seen with ductal cancer - so not a definitive feature of lobular - any change needs to be evaluated by your doc |
| Dennis Keim @denniskeim RT @Adrianvlee: Nice clinical review on ILC https://t.co/1M57BSLsnh #BCSM |
| Lobular Breast Cancer Alliance @LobularBCA T1: Lobular breast cancer is a different disease. But it's treated with the same protocols as #IDC #bcsm That is not good enough |
| IBC Research Fdn @IBCResearch RT @jrgralow: T1: T1: Invasive lobular carcinoma comprises about 10-15% of breast cancers. Doesn't make a lump, so difficult to find on imaging and physical exam! Most patients report a thickening, or subtle difference between the two breasts. #bcsm |
| Dr. Steffi Oesterreich @oesterreichs @stales @double_whammied @LobularBCA @jrgralow Although "only" consisting of 10-15% of all breast cancers, this translated into approximately 20,000 new cases of LBC in the US alone #BCSM |
| Double Whammy @double_whammied T1: #Lobular also doesn't image as well as ductal. My mammogram saw nothing, even on the day the ultrasound found 4 masses. We need more research on imaging for #lobular. #BCSM |
| Double Whammy @double_whammied RT @oesterreichs: @stales @double_whammied @LobularBCA @jrgralow It is the second most common histologic subtype of breast cancer, representing 10-15% of all diagnosed breast cancers #BCSM |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @jrgralow: T1: T1: Invasive lobular carcinoma comprises about 10-15% of breast cancers. Doesn't make a lump, so difficult to find on imaging and physical exam! Most patients report a thickening, or subtle difference between the two breasts. #bcsm |
| Dr. Steffi Oesterreich @oesterreichs @MjoconorMary @ihatebreastcanc @Adrianvlee ILC tend to grow slower with lower proliferation markers and also tend to recur later #BCSM |
 | Barbara Jacoby @letlifehappen RT @DiepFlapBreast: This year, #PRMAPlasticSurgery surgeon Dr. Oscar Ochoa will be joining the team of experts presenting at the FORCE Conference. https://t.co/tkoXHR1iSe #BreastCancer #BRCA #bcsm |
| Dr. Kelly Shanahan @stage4kelly @IBCResearch Hi Ginny. Thought you were going to rest, hint, hint. #bcsm |
| Elizabeth Viggiano @EV11PDX imaging doesn't detect any of my peritoneal/ovarian or colon mets... #bcsm |
| Dennis Keim @denniskeim RT @oesterreichs: @stales @double_whammied @LobularBCA @jrgralow It is the second most common histologic subtype of breast cancer, representing 10-15% of all diagnosed breast cancers #BCSM |
| Katherine OBrien @ihatebreastcanc RT @oesterreichs: @MjoconorMary @ihatebreastcanc @Adrianvlee ILC tend to grow slower with lower proliferation markers and also tend to recur later #BCSM |
| Dr. Kelly Shanahan @stage4kelly @akknowles1 Give your H a big hug - and keep one for yourself momma! #bcsm |
| Alicia C. Staley @stales RT @LobularBCA T1: Lobular breast cancer is a different disease. But it's treated with the same protocols as #IDC #bcsm |
| Dennis Keim @denniskeim RT @jrgralow: T1: T1: Invasive lobular carcinoma comprises about 10-15% of breast cancers. Doesn't make a lump, so difficult to find on imaging and physical exam! Most patients report a thickening, or subtle difference between the two breasts. #bcsm |
| Julie Gralow @jrgralow T1: A distinguishing biologic feature of lobular breast cancer is the lack of a cell-to-cell adhesion gene (CDH1) and associated protein (e-cadherin), which makes the cells form single-file lines instead of lumps! They don't stick together. Again, no lumps! #bcsm |
 | Zula @ZulaQi RT @double_whammied: T1: T1: #Lobular also doesn't image as well as ductal. My mammogram saw nothing, even on the day the ultrasound found 4 masses. We need more research on imaging for #lobular. #BCSM |
| Lobular Breast Cancer Alliance @LobularBCA @oesterreichs @stales @double_whammied @jrgralow With 40,000 new cases a year, ILC is the #6 most frequently diagnosed cancer of women in the US #bcsm |
| Dr. Steffi Oesterreich @oesterreichs RT @jrgralow: T1: T1: A distinguishing biologic feature of lobular breast cancer is the lack of a cell-to-cell adhesion gene (CDH1) and associated protein (e-cadherin), which makes the cells form single-file lines instead of lumps! They don't stick together. Again, no lumps! #bcsm |
| Double Whammy @double_whammied That's totally what happened with me, @DrAttai. Had mamms for YEARS and always got an all-clear. Wasn't until I saw a change in my breast that they found my stage 3A lobular. Do docs all know this? #BCSM |
| Lex @Lex_in_CO @jrgralow Interesting. Wasn’t diagnosed as lobular but does sound very much like mine. #bcsm. I felt like one was heavier no discernible lump. |
| Julie Gralow @jrgralow T1: Also, 2 subtypes of invasive lobular breast cancer - classical (the majority) and pleomorphic (more aggressive features). #bcsm |
| Alicia C. Staley @stales RT @TalkIBC No lump. yes, there are breast cancers without a lump. #bcsm |
| Dr. Kelly Shanahan @stage4kelly Learning so much about #ILC from some of the top experts in the field #bcsm |
 | Kala, PhD MSCE @nambiar_kala RT @jrgralow: T1: T1: A distinguishing biologic feature of lobular breast cancer is the lack of a cell-to-cell adhesion gene (CDH1) and associated protein (e-cadherin), which makes the cells form single-file lines instead of lumps! They don't stick together. Again, no lumps! #bcsm |
| IBC Research Fdn @IBCResearch @stage4kelly Hi Kelly....I'll mostly read 😊 always want to learn. TY for caring & holding space. 😘 #bcsm |
| Alicia C. Staley @stales RT @jrgralow T1: Also, 2 subtypes of invasive lobular breast cancer - classical (the majority) & pleomorphic -more aggressive features #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA @EV11PDX RECIST measurable disease is a critical issue for #lobular patients. If patients can't qualify for studies, we will never learn about this disease #bcsm #amsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer RT @double_whammied: T1: T1: #Lobular also doesn't image as well as ductal. My mammogram saw nothing, even on the day the ultrasound found 4 masses. We need more research on imaging for #lobular. #BCSM |
| Double Whammy @double_whammied More on this #lobular feature, e-cadherin, here: https://t.co/qXICe3IQDQ #bcsm |
| Julie Gralow @jrgralow RT @stales: RT @TalkIBC No lump. yes, there are breast cancers without a lump. #bcsm |
| Dr. Kelly Shanahan @stage4kelly @double_whammied Or markers. Or something to find this sneaky form of BC. #bcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #BCSM |
| Alicia C. Staley @stales Yes, indeed! That's how we roll on #BCSM RT @stage4kelly Learning so much about #ILC from some of the top experts in the field #bcsm |
| Dr. Kelly Shanahan @stage4kelly RT @oesterreichs: @stales @double_whammied @LobularBCA @jrgralow Although "only" consisting of 10-15% of all breast cancers, this translated into approximately 20,000 new cases of LBC in the US alone #BCSM |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @oesterreichs: @stales @double_whammied @LobularBCA @jrgralow #bcsm The main difference is that the cells lack e-cadherin, which glues cells together. As a result, the tumor cells grow in a spider-web like fashion and not as a lump |
| Alicia C. Staley @stales @fckboobiecancer hello! #bcsm |
| Dr. Kelly Shanahan @stage4kelly RT @oesterreichs: @MjoconorMary @ihatebreastcanc @Adrianvlee ILC tend to grow slower with lower proliferation markers and also tend to recur later #BCSM |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @double_whammied: More on this #lobular feature, e-cadherin, here: More on this #lobular feature, e-cadherin, here: https://t.co/qXICe3IQDQ #bcsm |
| Alicia C. Staley @stales RT @double_whammied More on #lobular -- e-cadherin, here: https://t.co/ZJf9i1tatA #bcsm |
| Katherine OBrien @ihatebreastcanc #bcsm #lobmob #lobularbreastcancer |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @LobularBCA: @EV11PDX RECIST measurable disease is a critical issue for #lobular patients. If patients can't qualify for studies, we will never learn about this disease #bcsm #amsm |
| Dr. Kelly Shanahan @stage4kelly RT @jrgralow: T1: T1: A distinguishing biologic feature of lobular breast cancer is the lack of a cell-to-cell adhesion gene (CDH1) and associated protein (e-cadherin), which makes the cells form single-file lines instead of lumps! They don't stick together. Again, no lumps! #bcsm |
| Double Whammy @double_whammied Yes there are! Both #lobular and #inflammatory #breastcancer are weird in that they don't necessarily make a lump. Look for a change in your breast, not necessarily a lump. #bcsm |
| Alicia C. Staley @stales @ihatebreastcanc welcome! #bcsm |
| Lobular Research @LobularResearch Any trials or progress with imaging diagnostics, esp for post-diagnosis surveillance? (metastatic population often denied trial enrollment due to RECIST criteria). #lobular #BCSM |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @LobularBCA: @EV11PDX RECIST measurable disease is a critical issue for #lobular patients. If patients can't qualify for studies, we will never learn about this disease #bcsm #amsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @stage4kelly: @double_whammied Or markers. Or something to find this sneaky form of BC. #bcsm |
| Alicia C. Staley @stales Welcome to all the new folks joining the chat tonight! #bcsm |
| Katherine OBrien @ihatebreastcanc RT @LobularBCA: T1: T1: Lobular breast cancer is a different disease. But it's treated with the same protocols as #IDC #bcsm That is not good enough |
| Dennis Keim @denniskeim @Jpete008 What's a mot cat scan? #bcsm |
| The IBC Network Foundation @TalkIBC I knew a lady who wanted an lob mob clinic at MDA like the IBC clinic. She couldn't get the pts population. What can we do? #bcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #BCSM |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @double_whammied: Yes there are! Both #lobular and #inflammatory #breastcancer are weird in that they don't necessarily make a lump. Look for a change in your breast, not necessarily a lump. #bcsm |
| Alicia C. Staley @stales Hello to all the lurkers :-) #bcsm |
| Katherine OBrien @ihatebreastcanc RT @stales: @ihatebreastcanc welcome! #bcsm |
| Dr. Kelly Shanahan @stage4kelly RT @jrgralow: T1: T1: Also, 2 subtypes of invasive lobular breast cancer - classical (the majority) and pleomorphic (more aggressive features). #bcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #BCSM |
 | flora migyanka @maggiemoo09 RT @jrgralow: T1: T1: A distinguishing biologic feature of lobular breast cancer is the lack of a cell-to-cell adhesion gene (CDH1) and associated protein (e-cadherin), which makes the cells form single-file lines instead of lumps! They don't stick together. Again, no lumps! #bcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #BCSM |
| flora migyanka @maggiemoo09 RT @oesterreichs: Join us for a discussion on ILC tonight 9pm EST. #bcsm |
| Kala, PhD MSCE @nambiar_kala RT @jrgralow: T1: T1: Also, 2 subtypes of invasive lobular breast cancer - classical (the majority) and pleomorphic (more aggressive features). #bcsm |
| Dr. Kelly Shanahan @stage4kelly @LobularBCA @EV11PDX Us bone mets folks have the same issue. #bcsm |
| Alicia C. Staley @stales RT @double_whammied: Yes there are! Both #lobular and #inflammatory #breastcancer are weird in that they don't necessarily make a lump. Look for a change in your breast, not necessarily a lump. #bcsm |
| Double Whammy @double_whammied Yes, #LobularBC's #metastatic spread pattern can be very different too. This is very important for both PCPs and oncs to know! #BCSM |
| Dennis Keim @denniskeim RT @jrgralow: T1: T1: Also, 2 subtypes of invasive lobular breast cancer - classical (the majority) and pleomorphic (more aggressive features). #bcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #BCSM This |
| Alicia C. Staley @stales RT @LobularBCA: @oesterreichs @stales @double_whammied @jrgralow With 40,000 new cases a year, ILC is the #6 most frequently diagnosed cancer of women in the US #bcsm |
| The IBC Network Foundation @TalkIBC @stales reading more than comments but here and RT! #bcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #BCSM |
| IBC Research Fdn @IBCResearch @jrgralow Interesting. #IBC is high in e-cadherin yet usually no lump. Most are ductal in origin though. #bcsm |
| Dr. Deanna Attai @DrAttai @double_whammied #bcsm yes but inflammatory CA (IBC) usually is ductal, not lobular. But similarities in terms of sneakiness |
| Double Whammy @double_whammied Really great points, @DrAttai! #BCSM |
| Dennis Keim @denniskeim RT @stales: RT @TalkIBC No lump. yes, there are breast cancers without a lump. #bcsm |
 | Jamie Holloway, PhD @jamienholloway Hi friends, sorry I'm late to the party! Trying to keep a normal schedule in the summer is tough! #bcsm |
| flora migyanka @maggiemoo09 RT @double_whammied: Join me @jrgralow and @oesterreichs for a special #bcsm tweetchat on "sneaky" #lobular #breastcancer or #ILC. #lobmob Mon, Aug 13 | 6 pm PT/9pm ET @mjsikora @Prof_Riggins hope u can join the fun! Thx 4 the #bcsm love @stales @DrAttai ❤❤ https://t.co/JfDwYbqEy4 |
| Hillary (Stires) Andrews, PhD @HillStirSci @LobularResearch Hopefully! So far they've found 18F-Fluciclovine may be better than standard imaging. Future studies will hopefully show whether this is true in a larger cohort. https://t.co/6SJHyozSsf #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @IBCResearch: @jrgralow Interesting. #IBC is high in e-cadherin yet usually no lump. Most are ductal in origin though. #bcsm |
 | Liza B @itsthebunk RT @double_whammied: Yes, #LobularBC's #metastatic spread pattern can be very different too. This is very important for both PCPs and oncs to know! #BCSM |
| flora migyanka @maggiemoo09 RT @Prof_Riggins: This promises great talks from @mjsikora @oesterreichs @Adrianvlee and Myles Brown @DanaFarber on #lobular breast cancer #bcsm https://t.co/DXXVaC1mzO |
| Adrian Lee @Adrianvlee @double_whammied Our recent paper showing loss of E-cadherin (CDH1) in ILC results in increased growth factor (IGF) signaling - a potential new therapeutic target #BCSM https://t.co/xxgyoVPml6 |
| The IBC Network Foundation @TalkIBC @DrAttai @double_whammied yes and can be both but my question is can we get a center to be a center of excellence like MDA for IBC? #bcsm |
| Alicia C. Staley @stales @jamienholloway hey hey hey! #bcsm |
| Double Whammy @double_whammied Just a reminder to all in the #BCSM tweetchat on #lobular #breastcancer (esp myself) to add #BCSM to your tweets! |
| Elizabeth Viggiano @EV11PDX Also 18-FES, but neither approved so can't get insurance to approve today #bcsm |
| Dr. Kelly Shanahan @stage4kelly RT @HillStirSci: @LobularResearch Hopefully! So far they've found 18F-Fluciclovine may be better than standard imaging. Future studies will hopefully show whether this is true in a larger cohort. https://t.co/6SJHyozSsf #bcsm |
| Alicia C. Staley @stales @TalkIBC Hello, hello!! #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @Adrianvlee: @double_whammied Our recent paper showing loss of E-cadherin (CDH1) in ILC results in increased growth factor (IGF) signaling - a potential new therapeutic target #BCSM https://t.co/xxgyoVPml6 |
| Lex @Lex_in_CO Yes. Mine was also highly hormone sensitive. Hard to measure a discernible mass but I don’t think it was classed as “lobular” #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @HillStirSci: @LobularResearch Hopefully! So far they've found 18F-Fluciclovine may be better than standard imaging. Future studies will hopefully show whether this is true in a larger cohort. https://t.co/6SJHyozSsf #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @Adrianvlee: @double_whammied Our recent paper showing loss of E-cadherin (CDH1) in ILC results in increased growth factor (IGF) signaling - a potential new therapeutic target #BCSM https://t.co/xxgyoVPml6 |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @HillStirSci: @LobularResearch Hopefully! So far they've found 18F-Fluciclovine may be better than standard imaging. Future studies will hopefully show whether this is true in a larger cohort. https://t.co/6SJHyozSsf #bcsm |
| Double Whammy @double_whammied Wow, this is exciting. Thanks for sharing that @Adrianvlee, #BCSM #goresearch |
| Double Whammy @double_whammied RT @Lex_in_CO: Yes. Mine was also highly hormone sensitive. Hard to measure a discernible mass but I don’t think it was classed as “lobular” #bcsm |
| Dr. Kelly Shanahan @stage4kelly A major frustration is insurance coverage for promising but not approved techniques #bcsm |
| Jamie Holloway, PhD @jamienholloway @itsthebunk Hi! Was thinking about you today! We need to catch up soon! #bcsm |
| Matthew J. Sikora, PhD @mjsikora @HillStirSci @LobularResearch There was discussion at the first lobular symposium over whether radiolabeled Estradiol might be ideal for ILC since it's so ER-positive, but not aware of any recent data. #bcsm |
| Julie Gralow @jrgralow T1: Classic breast ca staging doesn't fit for lobular - because of "single-file" growth, lobulars extend long distances. Because "T" in "TNM" is length, lobulars always reported as big. But within same size, lots less cancer cells than w/ ductal! #bcsm https://t.co/IXIkXNMmIy |
 | Angela Alexander PhD @thecancergeek Howdy #bcsm. Running late tonight, I'll need to catch up with y'all for a few mins #bcsm |
| The IBC Network Foundation @TalkIBC RT @jrgralow: T1: T1: Classic breast ca staging doesn't fit for lobular - because of "single-file" growth, lobulars extend long distances. Because "T" in "TNM" is length, lobulars always reported as big. But within same size, lots less cancer cells than w/ ductal! #bcsm https://t.co/IXIkXNMmIy |
| Double Whammy @double_whammied RT @jrgralow: T1: T1: Classic breast ca staging doesn't fit for lobular - because of "single-file" growth, lobulars extend long distances. Because "T" in "TNM" is length, lobulars always reported as big. But within same size, lots less cancer cells than w/ ductal! #bcsm https://t.co/IXIkXNMmIy |
| Hillary (Stires) Andrews, PhD @HillStirSci @DrAttai @jrgralow That's our general understanding! https://t.co/6ZiN3UzMGF #bcsm |
| Liza B @itsthebunk @ndenduluri1 @LobularResearch Thanks :) #bcsm |
| Dr. Deanna Attai @DrAttai @itsthebunk @LobularResearch sorry for wikipedia ref it was the first that popped up #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @jrgralow: T1: T1: Classic breast ca staging doesn't fit for lobular - because of "single-file" growth, lobulars extend long distances. Because "T" in "TNM" is length, lobulars always reported as big. But within same size, lots less cancer cells than w/ ductal! #bcsm https://t.co/IXIkXNMmIy |
| Katherine OBrien @ihatebreastcanc RT @HillStirSci: @LobularResearch Hopefully! So far they've found 18F-Fluciclovine may be better than standard imaging. Future studies will hopefully show whether this is true in a larger cohort. https://t.co/6SJHyozSsf #bcsm |
| Liza B @itsthebunk @DrAttai @LobularResearch Thanks! #bcsm |
 | patty spears @paspears88 @oesterreichs @ihatebreastcanc A friend was diagnosed with metastatic lobular -- it was around her stomach.... it seemed hard to monitor so she was always a anxious about whether therapy was working.... it was so different for her compared to others in the group.... #bcsm |
| Katherine OBrien @ihatebreastcanc RT @jrgralow: T1: T1: Invasive lobular carcinoma comprises about 10-15% of breast cancers. Doesn't make a lump, so difficult to find on imaging and physical exam! Most patients report a thickening, or subtle difference between the two breasts. #bcsm |
| Double Whammy @double_whammied I'd love to hear more about this, @mjsikora. #BCSM |
| Katherine OBrien @ihatebreastcanc RT @Adrianvlee: @double_whammied Our recent paper showing loss of E-cadherin (CDH1) in ILC results in increased growth factor (IGF) signaling - a potential new therapeutic target #BCSM https://t.co/xxgyoVPml6 |
 | Phyllis Johnson @mrsphjohnson RT @jrgralow: T1: T1: Invasive lobular carcinoma comprises about 10-15% of breast cancers. Doesn't make a lump, so difficult to find on imaging and physical exam! Most patients report a thickening, or subtle difference between the two breasts. #bcsm |
| Katherine OBrien @ihatebreastcanc RT @jrgralow: T1: T1: A distinguishing biologic feature of lobular breast cancer is the lack of a cell-to-cell adhesion gene (CDH1) and associated protein (e-cadherin), which makes the cells form single-file lines instead of lumps! They don't stick together. Again, no lumps! #bcsm |
| Julie Gralow @jrgralow Classical lobulars are strongly ER/PR+, HER2 negative, low grade. Little value to chemo and lots of benefit from endocrine. But all endocrine might not be the same! Ongoing studies. #bcsm https://t.co/D8JX2mq6IW |
| Dr. Kelly Shanahan @stage4kelly @mjsikora @HillStirSci @LobularResearch Would there be that same problem of not enough mass for an imaging technique to pick up lobular, since it’s more likely to be in sheets then clumps? Or is this marker so much more avid for lobular that it will register on imaging? #bcsm |
| Dr. Deanna Attai @DrAttai @mjsikora @HillStirSci @LobularResearch #bcsm that would be pretty cool! |
| Dr. Steffi Oesterreich @oesterreichs @akknowles1 #bcsm Interesting question, we don't know much about it. Limited understanding, we hope that genomics and transcriptomics will help to improve understanding. Great start with https://t.co/lBcaSPAb8i |
| Katherine OBrien @ihatebreastcanc RT @jrgralow: Lots of lobular breast cancer patients on this chat! #bcsm |
 | Strong Heart Now @StrongHeartNow1 @stales Hi, yes I’m lurking. #bcsm #bcsm |
| Double Whammy @double_whammied RT @stage4kelly: A major frustration is insurance coverage for promising but not approved techniques #bcsm |
| Lex @Lex_in_CO Should each met site be tested??? #bcsm |
| Dr. Kelly Shanahan @stage4kelly #BCSM My brain is loving all this learning! Thank you to all the experts here teaching us so much about #ILC |
| Katherine OBrien @ihatebreastcanc RT @jrgralow: T1: T1: Also, 2 subtypes of invasive lobular breast cancer - classical (the majority) and pleomorphic (more aggressive features). #bcsm |
| Katherine OBrien @ihatebreastcanc RT @mjsikora: Hello BCSM! Matt - scientist and lobular researcher from Colorado. Long time BCSM lurker. #bcsm |
| Katherine OBrien @ihatebreastcanc RT @LobularResearch: Any trials or progress with imaging diagnostics, esp for post-diagnosis surveillance? (metastatic population often denied trial enrollment due to RECIST criteria). #lobular #BCSM |
| Dr. Deanna Attai @DrAttai @Lex_in_CO #bcsm generally recommended to biopsy new met site but not all of them |
| Katherine OBrien @ihatebreastcanc RT @paspears88: @oesterreichs @ihatebreastcanc A friend was diagnosed with metastatic lobular -- it was around her stomach.... it seemed hard to monitor so she was always a anxious about whether therapy was working.... it was so different for her compared to others in the group.... #bcsm |
| Dennis Keim @denniskeim RT @jrgralow: T1: T1: A distinguishing biologic feature of lobular breast cancer is the lack of a cell-to-cell adhesion gene (CDH1) and associated protein (e-cadherin), which makes the cells form single-file lines instead of lumps! They don't stick together. Again, no lumps! #bcsm |
| Julie Gralow @jrgralow Would be great if we could define a role for IGF (insulin-like growth factor) targeted agents in invasive lobular breast cancer. #bcsm https://t.co/hKJzEYgSsN |
| Dennis Keim @denniskeim RT @Adrianvlee: @double_whammied Our recent paper showing loss of E-cadherin (CDH1) in ILC results in increased growth factor (IGF) signaling - a potential new therapeutic target #BCSM https://t.co/xxgyoVPml6 |
| Liza B @itsthebunk @DrAttai @LobularResearch No worries! It helped! #bcsm |
| Liza B @itsthebunk @ndenduluri1 @LobularResearch Thanks! #bcsm |
| Dennis Keim @denniskeim RT @double_whammied: Yes there are! Both #lobular and #inflammatory #breastcancer are weird in that they don't necessarily make a lump. Look for a change in your breast, not necessarily a lump. #bcsm |
| Dr. Kelly Shanahan @stage4kelly Research, smart research asking the right questions, is what we all need. #ResearchNotRibbons #bcsm |
 | Jane Peterson @Jpete008 @jrgralow At least I’m classic in something. #bcsm |
| Dennis Keim @denniskeim RT @Lex_in_CO: Yes. Mine was also highly hormone sensitive. Hard to measure a discernible mass but I don’t think it was classed as “lobular” #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @jrgralow: Would be great if we could define a role for IGF (insulin-like growth factor) targeted agents in invasive lobular breast cancer. #bcsm https://t.co/hKJzEYgSsN |
| Dennis Keim @denniskeim RT @double_whammied: T1: T1: #Lobular also doesn't image as well as ductal. My mammogram saw nothing, even on the day the ultrasound found 4 masses. We need more research on imaging for #lobular. #BCSM |
| Dennis Keim @denniskeim RT @double_whammied: Yes, #LobularBC's #metastatic spread pattern can be very different too. This is very important for both PCPs and oncs to know! #BCSM |
| Lobular Breast Cancer Alliance @LobularBCA Endocrine response trial inclusionary of ILC at @Otto_DFCI #bcsm #lobular |
 | Mary O'Connor @MjoconorMary @mjsikora @HillStirSci @LobularResearch #bcsm this sounds like an excellent approach but who should be targeted premenopausal women have such variation in breast cyclically and high density so may be difficult to detect changes |
| Alicia C. Staley @stales T2 coming up! #bcsm |
| Lobular Research @LobularResearch Probably getting way ahead of myself... but anyone exploring Immuno-Oncology approaches beyond checkpoint blockade? Any potential/attractive cell surface targets that could be exploited with CAR-T or CAR-NK approaches? #BCSM #lobular |
| Double Whammy @double_whammied Here's a clinical trial that's specifically looking at #endocrine response in lobular #breastcancer Multi center trial across the U.S. #BCSM https://t.co/Y7KpETQo8Y |
| Alicia C. Staley @stales Great conversation so far - I'm learning so much! #bcsm |
| Dr. Kelly Shanahan @stage4kelly @itsthebunk It makes my brain hurt, but it’s a good kind of pain, just like after a workout in the gym. #bcsm |
| Double Whammy @double_whammied RT @stage4kelly: @itsthebunk It makes my brain hurt, but it’s a good kind of pain, just like after a workout in the gym. #bcsm |
| Matthew J. Sikora, PhD @mjsikora @jrgralow A key focus in my lab is trying to understand why ER behaves differently in #lobular, and endocrine rx work differently. We think it might be linked to lack of chemo response too, but early stages of the research. #bcsm |
 | Shanna Marzilli @Shanna_Marzilli @jrgralow Value of chemo with high oncotype? #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @double_whammied: Here's a clinical trial that's specifically looking at #endocrine response in lobular #breastcancer Multi center trial across the U.S. #BCSM https://t.co/Y7KpETQo8Y |
| Dennis Keim @denniskeim RT @ndenduluri1: |
| Mary O'Connor @MjoconorMary @jrgralow #bcsm another major point of difference |
| Dr. Kelly Shanahan @stage4kelly RT @double_whammied: Here's a clinical trial that's specifically looking at #endocrine response in lobular #breastcancer Multi center trial across the U.S. #BCSM https://t.co/Y7KpETQo8Y |
| Double Whammy @double_whammied RT @mjsikora: @jrgralow A key focus in my lab is trying to understand why ER behaves differently in #lobular, and endocrine rx work differently. We think it might be linked to lack of chemo response too, but early stages of the research. #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @double_whammied: Here's a clinical trial that's specifically looking at #endocrine response in lobular #breastcancer Multi center trial across the U.S. #BCSM https://t.co/Y7KpETQo8Y |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @mjsikora: @jrgralow A key focus in my lab is trying to understand why ER behaves differently in #lobular, and endocrine rx work differently. We think it might be linked to lack of chemo response too, but early stages of the research. #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @LobularResearch: Probably getting way ahead of myself... but anyone exploring Immuno-Oncology approaches beyond checkpoint blockade? Any potential/attractive cell surface targets that could be exploited with CAR-T or CAR-NK approaches? #BCSM #lobular |
| Julie Gralow @jrgralow Another tricky feature of lobular ca - when they metastasize they also grow in sheets or lines, not lumps. VERY hard to monitor response. Many recurrent lobular cancers diagnosed when patient goes to abdominal/pelvic surgery for another reason. #bcsm https://t.co/y1ncOfdcFJ |
| Liza B @itsthebunk RT @double_whammied: Here's a clinical trial that's specifically looking at #endocrine response in lobular #breastcancer Multi center trial across the U.S. #BCSM https://t.co/Y7KpETQo8Y |
 | Stephanie Graff, MD, FACP, FASCO @DrSGraff RT @jrgralow: T1: T1: Classic breast ca staging doesn't fit for lobular - because of "single-file" growth, lobulars extend long distances. Because "T" in "TNM" is length, lobulars always reported as big. But within same size, lots less cancer cells than w/ ductal! #bcsm https://t.co/IXIkXNMmIy |
| Dr. Steffi Oesterreich @oesterreichs @LobularResearch #bcsm an interesting study starting to analyze immun-infiltrates in ILC: https://t.co/cLrteQSrpN |
| Lex @Lex_in_CO @jrgralow So what is “strongly” in the 90s or more only over 95%? #bcsm |
| Alicia C. Staley @stales T2: Can you share resources, sites, or orgs working on Lobular Breast Cancer? @double_whammied @oesterreichs @LobularBCA @jrgralow #bcsm |
| Stephanie Graff, MD, FACP, FASCO @DrSGraff Better late than never! Hello #bcsm |
 | When BC Happens @whenBChappens RT @matteolambe: |
| Double Whammy @double_whammied Patients shouldn't feel like the #chemo they had was a waste of time, tho, right @jrgralow? #BCSM |
| Alicia C. Staley @stales @DrSGraff welcome to the par-tay #bcsm |
| Julie Gralow @jrgralow important research! #bcsm https://t.co/HGxWw17l1D |
| Liza B @itsthebunk RT @double_whammied: Patients shouldn't feel like the #chemo they had was a waste of time, tho, right @jrgralow? #BCSM |
| Dennis Keim @denniskeim RT @mjsikora: @jrgralow A key focus in my lab is trying to understand why ER behaves differently in #lobular, and endocrine rx work differently. We think it might be linked to lack of chemo response too, but early stages of the research. #bcsm |
| Dennis Keim @denniskeim RT @jrgralow: Classical lobulars are strongly ER/PR+, HER2 negative, low grade. Little value to chemo and lots of benefit from endocrine. But all endocrine might not be the same! Ongoing studies. #bcsm https://t.co/D8JX2mq6IW |
| Lobular Breast Cancer Alliance @LobularBCA RT @jrgralow: Another tricky feature of lobular ca - when they metastasize they also grow in sheets or lines, not lumps. VERY hard to monitor response. Many recurrent lobular cancers diagnosed when patient goes to abdominal/pelvic surgery for another reason. #bcsm https://t.co/y1ncOfdcFJ |
| mary smith @ggmanonie RT @jrgralow: important research! #bcsm https://t.co/HGxWw17l1D |
| Double Whammy @double_whammied Thank you @DrAttai! I've met #lobmobbers who've had lumps. And many who haven't. #BCSM |
| Lobular Breast Cancer Alliance @LobularBCA RT @mjsikora: @jrgralow A key focus in my lab is trying to understand why ER behaves differently in #lobular, and endocrine rx work differently. We think it might be linked to lack of chemo response too, but early stages of the research. #bcsm |
| Dennis Keim @denniskeim RT @jrgralow: T1: T1: Classic breast ca staging doesn't fit for lobular - because of "single-file" growth, lobulars extend long distances. Because "T" in "TNM" is length, lobulars always reported as big. But within same size, lots less cancer cells than w/ ductal! #bcsm https://t.co/IXIkXNMmIy |
| The IBC Network Foundation @TalkIBC @DrAttai Same for IBC !0% have a lump. What is it for lob? #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @mjsikora: @jrgralow A key focus in my lab is trying to understand why ER behaves differently in #lobular, and endocrine rx work differently. We think it might be linked to lack of chemo response too, but early stages of the research. #bcsm |
| Elizabeth Viggiano @EV11PDX Dr.Attai- any treatment response differences between those ILC that form masses and those that don't? #bcsm |
| Adrian Lee @Adrianvlee @double_whammied @mjsikora Interesting clinical study (only 3 patients with ILC so preliminary) but showed potential value of estradiol PET for improved staging #BCSM https://t.co/D90sKyBqNt |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @mjsikora @jrgralow And in mine, we’re focused on why tamoxifen in particular may be less effective in #lobular than aromatase inhibitors #bcsm |
| Zula @ZulaQi RT @double_whammied: Yes there are! Both #lobular and #inflammatory #breastcancer are weird in that they don't necessarily make a lump. Look for a change in your breast, not necessarily a lump. #bcsm |
| Double Whammy @double_whammied Great question, Elizabeth! #BCSM |
| Lobular Breast Cancer Alliance @LobularBCA RT @Prof_Riggins: @mjsikora @jrgralow And in mine, we’re focused on why tamoxifen in particular may be less effective in #lobular than aromatase inhibitors #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @oesterreichs: @LobularResearch #bcsm an interesting study starting to analyze immun-infiltrates in ILC: @LobularResearch #bcsm an interesting study starting to analyze immun-infiltrates in ILC: https://t.co/cLrteQSrpN |
| Julie Gralow @jrgralow For classic lobular, ER/PR frequently above 90% positive with strong staining. Not always so strong, but rare to be ER/PR negative unless pleomorphic lobular. #bcsm https://t.co/B0J6aB0yZU |
| Dennis Keim @denniskeim RT @LobularResearch: Probably getting way ahead of myself... but anyone exploring Immuno-Oncology approaches beyond checkpoint blockade? Any potential/attractive cell surface targets that could be exploited with CAR-T or CAR-NK approaches? #BCSM #lobular |
| Julie Gralow @jrgralow RT @double_whammied: Here's a clinical trial that's specifically looking at #endocrine response in lobular #breastcancer Multi center trial across the U.S. #BCSM https://t.co/Y7KpETQo8Y |
| Dr. Deanna Attai @DrAttai @Shanna_Marzilli @jrgralow #bcsm yes, but most are low score |
| Dr. Steffi Oesterreich @oesterreichs @stales @double_whammied @LobularBCA @jrgralow #BCSM @LobularBCA keeps their website updated with important research and news about ILC. Including new clinical trials in patients with ILC |
| Dennis Keim @denniskeim RT @oesterreichs: @stales @double_whammied @LobularBCA @jrgralow #BCSM @LobularBCA keeps their website updated with important research and news about ILC. Including new clinical trials in patients with ILC |
| Elizabeth Viggiano @EV11PDX ER+/PR- pleomorphic here... #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @Adrianvlee: @double_whammied @mjsikora Interesting clinical study (only 3 patients with ILC so preliminary) but showed potential value of estradiol PET for improved staging #BCSM https://t.co/D90sKyBqNt |
| Double Whammy @double_whammied For those who'd like to learn more about @oesterreichs #lobular research, here's a link to her lab. #BCSM |
| Dr. Deanna Attai @DrAttai @Shanna_Marzilli @jrgralow #bcsm or present with node metastasis so treated with chemo w/o doing genomic testing - even though chemo may not be effective |
| Kala, PhD MSCE @nambiar_kala RT @jrgralow: Classical lobulars are strongly ER/PR+, HER2 negative, low grade. Little value to chemo and lots of benefit from endocrine. But all endocrine might not be the same! Ongoing studies. #bcsm https://t.co/D8JX2mq6IW |
| Hillary (Stires) Andrews, PhD @HillStirSci @DrAttai And some ovarian mets are ductal! We had a patient in tumor boards a few weeks ago with that. The way #lobular is defined is by ecadherin/p120 staining (at least at our cancer center). #bcsm |
| Alicia C. Staley @stales RT @jrgralow: For classic lobular, ER/PR frequently above 90% positive with strong staining. Not always so strong, but rare to be ER/PR negative unless pleomorphic lobular. #bcsm https://t.co/B0J6aB0yZU |
| Double Whammy @double_whammied RT @oesterreichs: @stales @double_whammied @LobularBCA @jrgralow #BCSM @LobularBCA keeps their website updated with important research and news about ILC. Including new clinical trials in patients with ILC |
| Matthew J. Sikora, PhD @mjsikora RT @Adrianvlee: @double_whammied @mjsikora Interesting clinical study (only 3 patients with ILC so preliminary) but showed potential value of estradiol PET for improved staging #BCSM https://t.co/D90sKyBqNt |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @jrgralow: For classic lobular, ER/PR frequently above 90% positive with strong staining. Not always so strong, but rare to be ER/PR negative unless pleomorphic lobular. #bcsm https://t.co/B0J6aB0yZU |
| Dennis Keim @denniskeim RT @oesterreichs: @LobularResearch #bcsm an interesting study starting to analyze immun-infiltrates in ILC: @LobularResearch #bcsm an interesting study starting to analyze immun-infiltrates in ILC: https://t.co/cLrteQSrpN |
| The IBC Network Foundation @TalkIBC RT @double_whammied: For those who'd like to learn more about @oesterreichs #lobular research, here's a link to her lab. #BCSM |
| Lex @Lex_in_CO @double_whammied @jrgralow One benefit of having chemo Before surgery was I FELT it working #BCSM gave me more confidence to continue |
| Lobular Breast Cancer Alliance @LobularBCA RT @Adrianvlee: @double_whammied @mjsikora Interesting clinical study (only 3 patients with ILC so preliminary) but showed potential value of estradiol PET for improved staging #BCSM https://t.co/D90sKyBqNt |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @HillStirSci: @DrAttai And some ovarian mets are ductal! We had a patient in tumor boards a few weeks ago with that. The way #lobular is defined is by ecadherin/p120 staining (at least at our cancer center). #bcsm |
| SouthrnBeachGrl @SouthrnBeachGrl @double_whammied Sigh, always for the post-menopausal women. The growing numbers of us who are pre are stuck with just one option! #bcsm |
| Dennis Keim @denniskeim RT @Lex_in_CO: @double_whammied @jrgralow One benefit of having chemo Before surgery was I FELT it working #BCSM gave me more confidence to continue |
| Lobular Breast Cancer Alliance @LobularBCA RT @jrgralow: important research! #bcsm https://t.co/HGxWw17l1D |
| Kala, PhD MSCE @nambiar_kala RT @jrgralow: T1: T1: Classic breast ca staging doesn't fit for lobular - because of "single-file" growth, lobulars extend long distances. Because "T" in "TNM" is length, lobulars always reported as big. But within same size, lots less cancer cells than w/ ductal! #bcsm https://t.co/IXIkXNMmIy |
| Double Whammy @double_whammied Always something, right? #breastcancer just HATES to follow rules. ; ) #bcsm |
| Dennis Keim @denniskeim RT @ndenduluri1: |
| Rod Ritchie @malefitness A case of a man with LBC: https://t.co/rRFEQLhnSG #bcsm |
| Gary L. Thompson @garyleethompson Such an amazing amount of clinical, anecdotal, and patient-driven knowledge on #lobular here... would be amazing if at moment of diagnosis this type of info could be in hands of patient and oncologist. #bcsm to the bedside!! |
| Katherine OBrien @ihatebreastcanc RT @double_whammied: Always something, right? #breastcancer just HATES to follow rules. ; ) #bcsm |
| Dr. Steffi Oesterreich @oesterreichs @double_whammied #BCSM https://t.co/XCz074mkoM Click this link to see our research on ILC! |
| Julie Gralow @jrgralow Of course not, all lobulars are not the same, just like all ductals are not the same! #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA RT @double_whammied: For those who'd like to learn more about @oesterreichs #lobular research, here's a link to her lab. #BCSM |
| Katherine OBrien @ihatebreastcanc RT @double_whammied: I'd love to hear more about this, @mjsikora. #BCSM |
| Alicia C. Staley @stales RT @HillStirSci: @DrAttai And some ovarian mets are ductal! We had a patient in tumor boards a few weeks ago with that. The way #lobular is defined is by ecadherin/p120 staining (at least at our cancer center). #bcsm |
| Katherine OBrien @ihatebreastcanc RT @Adrianvlee: @double_whammied @mjsikora Interesting clinical study (only 3 patients with ILC so preliminary) but showed potential value of estradiol PET for improved staging #BCSM https://t.co/D90sKyBqNt |
| Double Whammy @double_whammied RT @jrgralow: Of course not, all lobulars are not the same, just like all ductals are not the same! #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @garyleethompson: Such an amazing amount of clinical, anecdotal, and patient-driven knowledge on #lobular here... would be amazing if at moment of diagnosis this type of info could be in hands of patient and oncologist. #bcsm to the bedside!! |
| Dr. Kelly Shanahan @stage4kelly @EV11PDX Ooohhhhh. Interesting question. I ❤️ #bcsm |
| Katherine OBrien @ihatebreastcanc RT @jrgralow: For classic lobular, ER/PR frequently above 90% positive with strong staining. Not always so strong, but rare to be ER/PR negative unless pleomorphic lobular. #bcsm https://t.co/B0J6aB0yZU |
| Dr. Kelly Shanahan @stage4kelly RT @Adrianvlee: @double_whammied @mjsikora Interesting clinical study (only 3 patients with ILC so preliminary) but showed potential value of estradiol PET for improved staging #BCSM https://t.co/D90sKyBqNt |
| Double Whammy @double_whammied Thank you for sharing! #BCSM |
| Dennis Keim @denniskeim RT @jrgralow: For classic lobular, ER/PR frequently above 90% positive with strong staining. Not always so strong, but rare to be ER/PR negative unless pleomorphic lobular. #bcsm https://t.co/B0J6aB0yZU |
| Dr. Kelly Shanahan @stage4kelly RT @oesterreichs: @stales @double_whammied @LobularBCA @jrgralow #BCSM @LobularBCA keeps their website updated with important research and news about ILC. Including new clinical trials in patients with ILC |
| Katherine OBrien @ihatebreastcanc RT @stage4kelly: Research, smart research asking the right questions, is what we all need. #ResearchNotRibbons #bcsm |
| Dennis Keim @denniskeim RT @Prof_Riggins: @mjsikora @jrgralow And in mine, we’re focused on why tamoxifen in particular may be less effective in #lobular than aromatase inhibitors #bcsm |
| Matthew J. Sikora, PhD @mjsikora @SouthrnBeachGrl @double_whammied Hopefully we'll know more in the near future about aromatase inhibitor vs tamoxifen in pre-meno. Analysis of two large trials is pending, word is that logistics for ILC-based re-analyses are getting worked out. #bcsm |
| Dr. Kelly Shanahan @stage4kelly RT @garyleethompson: Such an amazing amount of clinical, anecdotal, and patient-driven knowledge on #lobular here... would be amazing if at moment of diagnosis this type of info could be in hands of patient and oncologist. #bcsm to the bedside!! |
| Howard Karpoff @doctorkarpoff RT @jrgralow: important research! #bcsm https://t.co/HGxWw17l1D |
| patty spears @paspears88 @jrgralow My friend ended up with gall bladder surgery and found out the HT was working ..... there was no cancer seen on her stomach.... but before that, she was a mess... worrying about what was going on... this was over 15 years ago... I would hope for more options today #bcsm |
| Angela Alexander PhD @thecancergeek @SouthrnBeachGrl @double_whammied Premenopausal women can take an AI too if they have their ovaries removed or pharmacologically suppressed. Makes quite a lot of sense especially in lobular cases where tamoxifen is proven inferior to AI! #bcsm |
| Jane Peterson @Jpete008 @jrgralow What about 100% one or the other? ? Mine was 100% PR, always seemed different than most. Any research? #bcsm |
| Double Whammy @double_whammied RT @mjsikora: @SouthrnBeachGrl @double_whammied Hopefully we'll know more in the near future about aromatase inhibitor vs tamoxifen in pre-meno. Analysis of two large trials is pending, word is that logistics for ILC-based re-analyses are getting worked out. #bcsm |
 | Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 @TomVargheseJr RT @jrgralow: Classical lobulars are strongly ER/PR+, HER2 negative, low grade. Little value to chemo and lots of benefit from endocrine. But all endocrine might not be the same! Ongoing studies. #bcsm https://t.co/D8JX2mq6IW |
| Dennis Keim @denniskeim RT @mjsikora: @HillStirSci @LobularResearch There was discussion at the first lobular symposium over whether radiolabeled Estradiol might be ideal for ILC since it's so ER-positive, but not aware of any recent data. #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @mjsikora: @SouthrnBeachGrl @double_whammied Hopefully we'll know more in the near future about aromatase inhibitor vs tamoxifen in pre-meno. Analysis of two large trials is pending, word is that logistics for ILC-based re-analyses are getting worked out. #bcsm |
| Dennis Keim @denniskeim RT @double_whammied: Patients shouldn't feel like the #chemo they had was a waste of time, tho, right @jrgralow? #BCSM |
| Double Whammy @double_whammied RT @thecancergeek: @SouthrnBeachGrl @double_whammied Premenopausal women can take an AI too if they have their ovaries removed or pharmacologically suppressed. Makes quite a lot of sense especially in lobular cases where tamoxifen is proven inferior to AI! #bcsm |
| Dr. Kelly Shanahan @stage4kelly @DrAttai @jrgralow Any budding postdocs lurking? This could be an interesting and valuable area of research #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA RT @mjsikora: @SouthrnBeachGrl @double_whammied Hopefully we'll know more in the near future about aromatase inhibitor vs tamoxifen in pre-meno. Analysis of two large trials is pending, word is that logistics for ILC-based re-analyses are getting worked out. #bcsm |
| Dennis Keim @denniskeim RT @stage4kelly: A major frustration is insurance coverage for promising but not approved techniques #bcsm |
| Julie Gralow @jrgralow Hmmm....I don’t know of any data on differences in treatments/response based on lump or not. I would think it would depend more on the biology. #bcsm |
| IBC Research Fdn @IBCResearch RT @malefitness: A case of a man with LBC: https://t.co/rRFEQLhnSG #bcsm |
| Dr. Steffi Oesterreich @oesterreichs #BCSM Our recent studies suggest that there are differences in immun-infiltration and cell metabolism between ILC and IDC, i.e. how cancer cells use nutrients https://t.co/LbR1YDl4js |
| Double Whammy @double_whammied RT @Prof_Riggins: @mjsikora @jrgralow And in mine, we’re focused on why tamoxifen in particular may be less effective in #lobular than aromatase inhibitors #bcsm |
| Lex @Lex_in_CO RT @double_whammied: Always something, right? #breastcancer just HATES to follow rules. ; ) #bcsm |
| Elizabeth Viggiano @EV11PDX Steffi-- any break-out for pleomorphic vs classical or Luminal B vs Luminal A #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA RT @oesterreichs: #BCSM Our recent studies suggest that there are differences in immun-infiltration and cell metabolism between ILC and IDC, i.e. how cancer cells use nutrients https://t.co/LbR1YDl4js |
 | Ginger Riley ~Eternal Optimist~ @gingerly21 RT @NCICancerStats: Black women are more likely than women of other races/ethnicities to die from breast #cancer. Learn more about this disease here: https://t.co/OWYkgGZP9a #BCSM https://t.co/2TwMfZcJQJ |
| Dr. Deanna Attai @DrAttai @malefitness #bcsm very rare! Thanks for sharing, @malefitness |
| Dennis Keim @denniskeim RT @double_whammied: Here's a clinical trial that's specifically looking at #endocrine response in lobular #breastcancer Multi center trial across the U.S. #BCSM https://t.co/Y7KpETQo8Y |
| Alicia C. Staley @stales RT @oesterreichs @double_whammied #BCSM https://t.co/pqy4gRu7bt Click this link to see our research on ILC! |
| Mary O'Connor @MjoconorMary @DrAttai @Shanna_Marzilli @jrgralow #bcsm taking a conservative approach but may not be of great therapeutic value, more research is really needed here |
| Dr. Kelly Shanahan @stage4kelly @jrgralow Is there a difference in e cadhedrin in the ones that form lumps versus don’t? Could this potentially be a target? I don’t have lobular so I’m not very familiar but I find all of this fascinating #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins This will be tremendously important for #lobular #bcsm |
| Alicia C. Staley @stales Thanks for sharing Rod RT @malefitness A case of a man with LBC: https://t.co/R2Xocf5RKH #bcsm |
| Double Whammy @double_whammied I would think that would be a super hard sell. Any patients care to weigh in on #ovariansuppression for #lobular? #BCSM |
| Rod Ritchie @malefitness From this study: "Although the rate of male breast cancer in Western countries is approximately 1%, in Tanzania and in Central Africa the rate is 6% or more." #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @oesterreichs: #BCSM Our recent studies suggest that there are differences in immun-infiltration and cell metabolism between ILC and IDC, i.e. how cancer cells use nutrients https://t.co/LbR1YDl4js |
| Lobular Research @LobularResearch Is it unrealistic to create an ILC tissue bank to accelerate discoveries? Can the tissue collected by the MBCproject be leveraged? I recall hearing that Genomic Health (OncotypeDX) has 30,000+ ILC tissue samples. Is that accessible / recyclable? #BCSM #lobular |
| Double Whammy @double_whammied RT @jrgralow: Hmmm....I don’t know of any data on differences in treatments/response based on lump or not. I would think it would depend more on the biology. #bcsm |
 | Hank Mardukas @DukeMardukas #bcsm Up to 15 percent of lobular carcinomas can be positive for e-cadherin. Presumed e-cadherin on the surface of tumor is there, but not functional. So get the similar lobular morphology on H&e stain. |
| Matthew J. Sikora, PhD @mjsikora @DrAttai @Prof_Riggins @jrgralow Not there yet. We just don't have the data for pre-meno yet, and it may be that the endocrine environment in pre-meno makes for a different disease (since ILC are so estrogen-driven). TBD, a couple large trials pending retrospective analysis. #bcsm |
| Alicia C. Staley @stales RT @garyleethompson: Such an amazing amount of clinical, anecdotal, and patient-driven knowledge on #lobular here... would be amazing if at moment of diagnosis this type of info could be in hands of patient and oncologist. #bcsm to the bedside!! |
| Julie Gralow @jrgralow PR is the most variable (and irreproducible) of the 3 main receptors we test for in breast cancer. We don’t think there is a big difference in endocrine response between, for example, a tumor with 70% vs 100% expression of ER/PR. #bcsm |
| Dr. Kelly Shanahan @stage4kelly RT @LobularResearch: Is it unrealistic to create an ILC tissue bank to accelerate discoveries? Can the tissue collected by the MBCproject be leveraged? I recall hearing that Genomic Health (OncotypeDX) has 30,000+ ILC tissue samples. Is that accessible / recyclable? #BCSM #lobular |
| Alicia C. Staley @stales RT @jrgralow: Of course not, all lobulars are not the same, just like all ductals are not the same! #bcsm |
| Jamie Holloway, PhD @jamienholloway @denniskeim Hi, Dennis, missed the meet and greet. Always love your "NED in Nebraska" tag! #bcsm |
| Alicia C. Staley @stales RT @jrgralow: Classical lobulars are strongly ER/PR+, HER2 negative, low grade. Little value to chemo and lots of benefit from endocrine. But all endocrine might not be the same! Ongoing studies. #bcsm https://t.co/D8JX2mq6IW |
| Double Whammy @double_whammied Do we need to start a new #ILC tissue bank or can we just leverage what already exists in current tissue banks? #lobular #BCSM |
| Kala, PhD MSCE @nambiar_kala RT @jrgralow: Another tricky feature of lobular ca - when they metastasize they also grow in sheets or lines, not lumps. VERY hard to monitor response. Many recurrent lobular cancers diagnosed when patient goes to abdominal/pelvic surgery for another reason. #bcsm https://t.co/y1ncOfdcFJ |
| Alicia C. Staley @stales RT @Prof_Riggins: @mjsikora @jrgralow And in mine, we’re focused on why tamoxifen in particular may be less effective in #lobular than aromatase inhibitors #bcsm |
| Double Whammy @double_whammied RT @stales: RT @oesterreichs @double_whammied #BCSM https://t.co/pqy4gRu7bt Click this link to see our research on ILC! |
| Alicia C. Staley @stales RT @malefitness: From this study: "Although the rate of male breast cancer in Western countries is approximately 1%, in Tanzania and in Central Africa the rate is 6% or more." #bcsm |
| Alicia C. Staley @stales RT @stage4kelly: Research, smart research asking the right questions, is what we all need. #ResearchNotRibbons #bcsm |
| Dr. Kelly Shanahan @stage4kelly @itsthebunk You too Liza! #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA RT @mjsikora: @DrAttai @Prof_Riggins @jrgralow Not there yet. We just don't have the data for pre-meno yet, and it may be that the endocrine environment in pre-meno makes for a different disease (since ILC are so estrogen-driven). TBD, a couple large trials pending retrospective analysis. #bcsm |
| Gary L. Thompson @garyleethompson @itsthebunk Thanks for joining and doing such a great job of self care!! #bcsm |
| Alicia C. Staley @stales RT @jrgralow: Another tricky feature of lobular ca - when they metastasize they also grow in sheets or lines, not lumps. VERY hard to monitor response. Many recurrent lobular cancers diagnosed when patient goes to abdominal/pelvic surgery for another reason. #bcsm https://t.co/y1ncOfdcFJ |
| Alicia C. Staley @stales RT @paspears88: @jrgralow My friend ended up with gall bladder surgery and found out the HT was working ..... there was no cancer seen on her stomach.... but before that, she was a mess... worrying about what was going on... this was over 15 years ago... I would hope for more options today #bcsm |
| Alicia C. Staley @stales @paspears88 @jrgralow hi patty! #bcsm |
| Dr. Steffi Oesterreich @oesterreichs @stage4kelly @DrAttai @jrgralow #BCSM Lee/Oesterreich Lab is looking to hire a motivated postdoc interested in understanding ILC https://t.co/if6r4PXQxJ |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @DrAttai @mjsikora @jrgralow It’s definitely a hard sell - data from ongoing prospective trials will be key #bcsm |
 | Iman Mohamed @ImmohMD @HillStirSci @DrAttai @jrgralow Agree. It can be frustrating to not see a significant response of large lobular cancers to neoadjuvant therapy. Endocrine therapy works better in the neoadjuvant setting for this pathology. #bcsm |
| Julie Gralow @jrgralow A definite maybe. Would discuss it for sure, but would factor in grade, amount of disease in the nodes, strength of Er/PR staining, patient preferences, etc! #bcsm |
| Alicia C. Staley @stales RT @jrgralow: PR is the most variable (and irreproducible) of the 3 main receptors we test for in breast cancer. We don’t think there is a big difference in endocrine response between, for example, a tumor with 70% vs 100% expression of ER/PR. #bcsm |
 | Kathy Gori @kathygori Checking in late...2x bc’er checking in fromfirey norther Ca and so far smokey but unburnt 🍷 Country #bcsm |
| Howard Karpoff @doctorkarpoff RT @Rawpimple: #bcsm Up to 15 percent of lobular carcinomas can be positive for e-cadherin. Presumed e-cadherin on the surface of tumor is there, but not functional. So get the similar lobular morphology on H&e stain. |
 | Andrea Borondy Kitts @findlungcancer Addressing clinician burnout in oncology Beyond Burnout https://t.co/ouOLQAoCuz @thenamedicine @crisalvaradomd #lcsm #bcsm |
| Double Whammy @double_whammied Re hormonal sensitivity and targets. Does progestin have extra significance for lobular? #BCSM |
 | Social✽Fly @socflyny @stales @double_whammied @oesterreichs @LobularBCA @jrgralow I'm there in spirit, but in actuality I'm in the hell that is Whole Foods 😁 ... Best Guests Ever! #bcsm |
| Dr. Deanna Attai @DrAttai @ImmohMD @HillStirSci @jrgralow hello my friend! Glad you've popped into #bcsm tonight! |
| Dr. Kelly Shanahan @stage4kelly Attention all smart science types! #bcsm |
| Mary O'Connor @MjoconorMary @thecancergeek @SouthrnBeachGrl @double_whammied #bcsm A difficult choice but worth considering |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @double_whammied: Re hormonal sensitivity and targets. Does progestin have extra significance for lobular? #BCSM |
| Kala, PhD MSCE @nambiar_kala RT @jrgralow: PR is the most variable (and irreproducible) of the 3 main receptors we test for in breast cancer. We don’t think there is a big difference in endocrine response between, for example, a tumor with 70% vs 100% expression of ER/PR. #bcsm |
| Double Whammy @double_whammied RT @stage4kelly: Attention all smart science types! #bcsm |
| Dennis Keim @denniskeim @kathygori Hey, Kathy! There seems to be no end to these fires. :( #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA @LobularResearch Histology is not aways requested or collected in #ILC studies #bcsm That's a first step |
| Matthew J. Sikora, PhD @mjsikora @double_whammied Need to leverage current to start. One issue is inconsistent methods for dx'ing ILC - gross histology vs Ecad/p120 stain. Not a lot of incentive to 'get it right' in the past, given lack of changes in rx. Need to figure it out, given loads of follow-up. #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @jrgralow: A definite maybe. Would discuss it for sure, but would factor in grade, amount of disease in the nodes, strength of Er/PR staining, patient preferences, etc! #bcsm |
| Double Whammy @double_whammied RT @socflyny: @stales @double_whammied @oesterreichs @LobularBCA @jrgralow I'm there in spirit, but in actuality I'm in the hell that is Whole Foods 😁 ... Best Guests Ever! #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @ImmohMD: @HillStirSci @DrAttai @jrgralow Agree. It can be frustrating to not see a significant response of large lobular cancers to neoadjuvant therapy. Endocrine therapy works better in the neoadjuvant setting for this pathology. #bcsm |
| Hillary (Stires) Andrews, PhD @HillStirSci @Rawpimple Similar ecad/p120 staining as well? Or just based off morphology? #BCSM |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @maggiemoo09 @mjsikora @jrgralow I wish we could! It’s something we’re working towards #bcsm |
| Julie Gralow @jrgralow If e-Cadherin is present, would more accurately call a mixed ductal/lobular or ductal with lobular features. #bcsm |
| Dr. Deanna Attai @DrAttai good question for @jrgralow and the researchers on the #bcsm chat tonight |
| Double Whammy @double_whammied RT @jrgralow: A definite maybe. Would discuss it for sure, but would factor in grade, amount of disease in the nodes, strength of Er/PR staining, patient preferences, etc! #bcsm |
| IBC Research Fdn @IBCResearch @itsthebunk Big hugs...we need to chat about #ReFresh sometime. Rest up ❤ #bcsm |
| Dr. Kelly Shanahan @stage4kelly @kathygori I’m amazed at how much smoke is here in Tahoe. You must be getting a lot from the Mendocino complex fire, plus Redding. #WeNeedRain #bcsm |
 | David Hedrick he/him @DrHedrick @stales @double_whammied @oesterreichs @LobularBCA @jrgralow Sneaking in for one of my favorite factoids. Lobular Carcinoma in Situ is I think the first and possibly only "cancer" to be downgraded to "not cancer" However it carries a significant risk of true carcinoma (even ductal), so mastectomy may still be warranted. #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @mjsikora: @DrAttai @Prof_Riggins @jrgralow Not there yet. We just don't have the data for pre-meno yet, and it may be that the endocrine environment in pre-meno makes for a different disease (since ILC are so estrogen-driven). TBD, a couple large trials pending retrospective analysis. #bcsm |
| IBC Research Fdn @IBCResearch RT @jrgralow: If e-Cadherin is present, would more accurately call a mixed ductal/lobular or ductal with lobular features. #bcsm |
| Hillary (Stires) Andrews, PhD @HillStirSci RT @oesterreichs: @stage4kelly @DrAttai @jrgralow #BCSM Lee/Oesterreich Lab is looking to hire a motivated postdoc interested in understanding ILC https://t.co/if6r4PXQxJ |
| Lex @Lex_in_CO @DrAttai @Prof_Riggins @mjsikora @jrgralow They considered me post meno in 2015 when new mets and switched to Ibrance and femara. But know early stage I might not have been so willing to race to menopause 🤷♀️ #bcsm |
| Dr. Steffi Oesterreich @oesterreichs @LobularResearch #BCSM We absolutely need increased access to metastatic ILC tissue. Participation in the metastatic breast cancer project is encouraged https://t.co/77PWvMX4Bv |
 | #Survivor3x ✌💚🕉🐾 @chigrl13 Yes, I'm lurking. #bcsm. |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @DrHedrick: @stales @double_whammied @oesterreichs @LobularBCA @jrgralow Sneaking in for one of my favorite factoids. Lobular Carcinoma in Situ is I think the first and possibly only "cancer" to be downgraded to "not cancer" However it carries a significant risk of true carcinoma (even ductal), so mastectomy may still be warranted. #bcsm |
| Jamie Holloway, PhD @jamienholloway RT @oesterreichs: @LobularResearch #BCSM We absolutely need increased access to metastatic ILC tissue. Participation in the metastatic breast cancer project is encouraged https://t.co/77PWvMX4Bv |
| Double Whammy @double_whammied RT @ndenduluri1: |
| #Survivor3x ✌💚🕉🐾 @chigrl13 RT @double_whammied: Yes, #LobularBC's #metastatic spread pattern can be very different too. This is very important for both PCPs and oncs to know! #BCSM |
| Lobular Breast Cancer Alliance @LobularBCA RT @oesterreichs: @LobularResearch #BCSM We absolutely need increased access to metastatic ILC tissue. Participation in the metastatic breast cancer project is encouraged https://t.co/77PWvMX4Bv |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @stage4kelly: @jrgralow Is there a difference in e cadhedrin in the ones that form lumps versus don’t? Could this potentially be a target? I don’t have lobular so I’m not very familiar but I find all of this fascinating #bcsm |
| Alicia C. Staley @stales @socflyny @double_whammied @oesterreichs @LobularBCA @jrgralow LOL. Great work multi-tasking. #BCSM |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @mjsikora: @double_whammied Need to leverage current to start. One issue is inconsistent methods for dx'ing ILC - gross histology vs Ecad/p120 stain. Not a lot of incentive to 'get it right' in the past, given lack of changes in rx. Need to figure it out, given loads of follow-up. #bcsm |
| Double Whammy @double_whammied More info here about how #lobular patients can sign up for the @MBC_Project. #BCSM https://t.co/oojHzxaT1G |
| Hillary (Stires) Andrews, PhD @HillStirSci RT @oesterreichs: @LobularResearch #BCSM We absolutely need increased access to metastatic ILC tissue. Participation in the metastatic breast cancer project is encouraged https://t.co/77PWvMX4Bv |
| Mary O'Connor @MjoconorMary @double_whammied #bcsm this is easier for premenopausal women over 45 but much more difficult before |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @oesterreichs: @LobularResearch #BCSM We absolutely need increased access to metastatic ILC tissue. Participation in the metastatic breast cancer project is encouraged https://t.co/77PWvMX4Bv |
| Julie Gralow @jrgralow Generally, cancers strongly positive for both ER and PR tend to have more endocrine sensitivity than those that are PR neg. But still plenty of responses even then. Weaker ER with PR negative would make me consider chemo more strongly (followed by endocrine) in early stage. #bcsm |
| Dennis Keim @denniskeim RT @oesterreichs: @LobularResearch #BCSM We absolutely need increased access to metastatic ILC tissue. Participation in the metastatic breast cancer project is encouraged https://t.co/77PWvMX4Bv |
| Double Whammy @double_whammied RT @jrgralow: Generally, cancers strongly positive for both ER and PR tend to have more endocrine sensitivity than those that are PR neg. But still plenty of responses even then. Weaker ER with PR negative would make me consider chemo more strongly (followed by endocrine) in early stage. #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @ndenduluri1: |
| Dr. Steffi Oesterreich @oesterreichs @mjsikora @double_whammied There is a large study ongoing comparing gross histology versus Ecad/p120. The data should be available later this year #BCSM |
| Alicia C. Staley @stales T3 coming up #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @smacdon932 @ndenduluri1 @double_whammied Yes, and I believe this is now being worked out, right @mjsikora? #bcsm |
| Dr. Kelly Shanahan @stage4kelly @DrHedrick @stales @double_whammied @oesterreichs @LobularBCA @jrgralow And what about atypical lobular hyperplasia as a possible marker of potential invasive cancer in either breast at some nebulous time in he future? #SoManyQuestions #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA #lobular needs to be analyzed within existing large studies #bcsm |
| Double Whammy @double_whammied RT @stales: @socflyny @double_whammied @oesterreichs @LobularBCA @jrgralow LOL. Great work multi-tasking. #BCSM |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @jrgralow: Generally, cancers strongly positive for both ER and PR tend to have more endocrine sensitivity than those that are PR neg. But still plenty of responses even then. Weaker ER with PR negative would make me consider chemo more strongly (followed by endocrine) in early stage. #bcsm |
| Matthew J. Sikora, PhD @mjsikora RT @oesterreichs: @mjsikora @double_whammied There is a large study ongoing comparing gross histology versus Ecad/p120. The data should be available later this year #BCSM |
| Lobular Breast Cancer Alliance @LobularBCA RT @oesterreichs: @mjsikora @double_whammied There is a large study ongoing comparing gross histology versus Ecad/p120. The data should be available later this year #BCSM |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @double_whammied: More info here about how #lobular patients can sign up for the @MBC_Project. #BCSM https://t.co/oojHzxaT1G |
| Dennis Keim @denniskeim RT @DrHedrick: @stales @double_whammied @oesterreichs @LobularBCA @jrgralow Sneaking in for one of my favorite factoids. Lobular Carcinoma in Situ is I think the first and possibly only "cancer" to be downgraded to "not cancer" However it carries a significant risk of true carcinoma (even ductal), so mastectomy may still be warranted. #bcsm |
| Alicia C. Staley @stales T3: Any new, promising research for Lobular Breast Cancer? #bcsm |
| Mary O'Connor @MjoconorMary @double_whammied #bcsm live cell lines also needed? |
| Alicia C. Staley @stales RT @LobularBCA #lobular needs to be analyzed within existing large studies #bcsm |
| #Survivor3x ✌💚🕉🐾 @chigrl13 RT @double_whammied: More info here about how #lobular patients can sign up for the @MBC_Project. #BCSM https://t.co/oojHzxaT1G |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @LobularBCA: #lobular needs to be analyzed within existing large studies #bcsm |
| Iman Mohamed @ImmohMD @DrAttai @HillStirSci @jrgralow Glad to be with you ! #Oncology #bcsm |
 | Kate @kate_petrides @ndenduluri1 @double_whammied I hope so! #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @stage4kelly: @DrHedrick @stales @double_whammied @oesterreichs @LobularBCA @jrgralow And what about atypical lobular hyperplasia as a possible marker of potential invasive cancer in either breast at some nebulous time in he future? #SoManyQuestions #bcsm |
| Dr. Kelly Shanahan @stage4kelly Yes! Please sign up for the @MBC_Project especially if you are metastatic lobular! #bcsm |
| Julie Gralow @jrgralow Right, new AJCC edition 8 staging makes LCIS no longer a cancer. But it still is associated with higher risk of future development of breast cancer (Both ductal and lobular) #bcsm |
| Alicia C. Staley @stales @chigrl13 i see you! xoxo #bcsm |
| Double Whammy @double_whammied What's the name of that study, @oesterreichs ? #BCSM |
 | Santhosh Ambika @RenoHemonc RT @HillStirSci: @LobularResearch Hopefully! So far they've found 18F-Fluciclovine may be better than standard imaging. Future studies will hopefully show whether this is true in a larger cohort. https://t.co/6SJHyozSsf #bcsm |
| Alicia C. Staley @stales --->>> Pass it on RT @stage4kelly Yes! Please sign up for the @MBC_Project especially if you are metastatic lobular! #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins This will be so welcomed #bcsm |
| Gary L. Thompson @garyleethompson @LobularBCA Like so much of #cancer research, it appears that connecting researchers to patients to data to clinical knowledge in closer to real time is key hurdle. #bcsm is awesome at breaking down the silos. Need to go further! |
| Dennis Keim @denniskeim RT @stales: --->>> Pass it on RT @stage4kelly Yes! Please sign up for the @MBC_Project especially if you are metastatic lobular! #bcsm |
| David Hedrick he/him @DrHedrick @DrAttai @stales @double_whammied @oesterreichs @LobularBCA @jrgralow Yes! I think the most recent AJCC calls it lobular hyperplasia (not high risk) vs. lobular neoplasia (high risk) but it makes for a difficult conversation. Good that we discuss increased screening and risk reducing meds vs mastectomy. #bcsm |
| Hillary (Stires) Andrews, PhD @HillStirSci @garyleethompson @LobularBCA Amen to that!!! #BCSM |
| Double Whammy @double_whammied This is excellent information, @DrAttai #BCSM @lobular |
| Kate @kate_petrides @MjoconorMary @double_whammied I don’t have lobular but started ovarian suppression at 26 and continued for slightly over 5 years until my recent mets dx. It’s a difficult transition, but I found it manageable for what I hoped was small OS benefit. Even larger? Easier sell, IMO. #bcsm |
| Double Whammy @double_whammied RT @garyleethompson: @LobularBCA Like so much of #cancer research, it appears that connecting researchers to patients to data to clinical knowledge in closer to real time is key hurdle. #bcsm is awesome at breaking down the silos. Need to go further! |
| Alicia C. Staley @stales RT @double_whammied: This is excellent information, @DrAttai #BCSM @lobular |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @stales @LobularBCA All of them #bcsm |
| Double Whammy @double_whammied RT @DrHedrick: @DrAttai @stales @double_whammied @oesterreichs @LobularBCA @jrgralow Yes! I think the most recent AJCC calls it lobular hyperplasia (not high risk) vs. lobular neoplasia (high risk) but it makes for a difficult conversation. Good that we discuss increased screening and risk reducing meds vs mastectomy. #bcsm |
| Julie Gralow @jrgralow Yep, ALH (atypical lobular hyperplasia) as well as ADH (atypical ductal hyperplasia) when found on a biopsy are both associated with increased risk for future development of breast cancer - anywhere in either breast. #bcsm |
| Dennis Keim @denniskeim RT @HillStirSci: @LobularResearch Hopefully! So far they've found 18F-Fluciclovine may be better than standard imaging. Future studies will hopefully show whether this is true in a larger cohort. https://t.co/6SJHyozSsf #bcsm |
| Dennis Keim @denniskeim RT @LobularResearch: Is it unrealistic to create an ILC tissue bank to accelerate discoveries? Can the tissue collected by the MBCproject be leveraged? I recall hearing that Genomic Health (OncotypeDX) has 30,000+ ILC tissue samples. Is that accessible / recyclable? #BCSM #lobular |
| Gary L. Thompson @garyleethompson @tayl0rth0mps0n (home from @uva) and @KylaGThompson say hello... Trader Joe's Chinese for dinner after #bcsm https://t.co/0OmsQ8C3zc |
| Dr. Kelly Shanahan @stage4kelly @DrAttai Any data on whether the presence of ALH may increase the risk of metastatic disease in those diagnosed with early-stage IDC? #Bcsm |
| Kathy Gori @kathygori @stage4kelly Yep, had to go to the onc as I couldn’t catch my breath last week. had a tests, everything is okay but my bronchia were inflamed from the smoke so I got two different inhalators to use and an N95 mask. my mistake was doing about 5 miles a day in bad air .so no exercise. #bcsm |
| Dennis Keim @denniskeim RT @jrgralow: Generally, cancers strongly positive for both ER and PR tend to have more endocrine sensitivity than those that are PR neg. But still plenty of responses even then. Weaker ER with PR negative would make me consider chemo more strongly (followed by endocrine) in early stage. #bcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer RT @malefitness: A case of a man with LBC: https://t.co/rRFEQLhnSG #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @MjoconorMary @double_whammied Limited numbers of cell/tumor models is one of the biggest challenges any #lobular research lab faces #bcsm |
| Dr. Deanna Attai @DrAttai @stage4kelly #bcsm not that I know of. Thought of as marker of increased risk for development of invasive breast CA, not necessarily development of mets |
| Adrian Lee @Adrianvlee @DrHedrick @stales @double_whammied @oesterreichs @LobularBCA @jrgralow Reis-Filho and King doing great work in this area showing that "LCIS is a clonal neoplastic lesion, and provides additional evidence that at least some LCIS are non-obligate precursors of ILC" #BCSM https://t.co/vjCUbiGHtQ |
| Julie Gralow @jrgralow Hmmm...not aware of any data suggesting this association. #bcsm https://t.co/EYhuYqLTJR |
 | Frank Ingram, MD @Chucktowndoc Ingram here. Community pathologist in NC. Been reading along. Hi! #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @oesterreichs: @LobularResearch #BCSM We absolutely need increased access to metastatic ILC tissue. Participation in the metastatic breast cancer project is encouraged https://t.co/77PWvMX4Bv |
| patty spears @paspears88 Lots of great links shared tonight...learning so much about #lobularbreastcancer. Definitely feel like there is a lot to learn through more research in diagnosis, treatment and managing #LBC . Thank you @oesterreichs @jrgralow @Adrianvlee @double_whammied #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @stales: --->>> Pass it on RT @stage4kelly Yes! Please sign up for the @MBC_Project especially if you are metastatic lobular! #bcsm |
| Julie Gralow @jrgralow RT @Adrianvlee: @DrHedrick @stales @double_whammied @oesterreichs @LobularBCA @jrgralow Reis-Filho and King doing great work in this area showing that "LCIS is a clonal neoplastic lesion, and provides additional evidence that at least some LCIS are non-obligate precursors of ILC" #BCSM https://t.co/vjCUbiGHtQ |
| Dr. Deanna Attai @DrAttai @Chucktowndoc #bcsm hello! great to have a pathologist on the chat! |
| Kathy Gori @kathygori @stage4kelly We had Alan’s brother and his wife visiting from DC, so lots of outdoor activity and I heard they’re even getting smoke in Canada and the Midwest #bcsm |
| Dr. Steffi Oesterreich @oesterreichs #BCSM T3 - research on ILC has been limited in the past at least in part due to limited availability of ILC models. We have made some recent progress, see: https://t.co/5DIbWgNzFv @mjsikora is doing excellent work in this area |
| Double Whammy @double_whammied This #lobular #breast #ROLO trial looks pretty interesting. It's in the UK. https://t.co/oNVfGgkeuu #BCSM |
| Dr. Deanna Attai @DrAttai @Chucktowndoc #bcsm feel free to chime in! |
| Lex @Lex_in_CO RT @paspears88: Lots of great links shared tonight...learning so much about #lobularbreastcancer. Definitely feel like there is a lot to learn through more research in diagnosis, treatment and managing #LBC . Thank you @oesterreichs @jrgralow @Adrianvlee @double_whammied #bcsm |
| Dennis Keim @denniskeim RT @Prof_Riggins: @MjoconorMary @double_whammied Limited numbers of cell/tumor models is one of the biggest challenges any #lobular research lab faces #bcsm |
| Matthew J. Sikora, PhD @mjsikora @Prof_Riggins @MjoconorMary @double_whammied We also run in to the problem that published organoid or mouse models may get reported as ILC, only to be NOT lobular once we do the Ecad/p120. Goes back to dx issues for histo v staining. #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA @stales Gelato Trial - a metastatic immunotherapy ILC trial in the Netherlands #bcsm https://t.co/ZKwWPIshfE |
| Double Whammy @double_whammied Thank you for joining the discussion! #lobular definitely needs to get more exposure AND more research #BCSM |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @oesterreichs: #BCSM T3 - research on ILC has been limited in the past at least in part due to limited availability of ILC models. We have made some recent progress, see: https://t.co/5DIbWgNzFv @mjsikora is doing excellent work in this area |
| Mary O'Connor @MjoconorMary @Prof_Riggins @double_whammied #bcsm we must advocate and fund this! |
| #Survivor3x ✌💚🕉🐾 @chigrl13 RT @double_whammied: This is excellent information, @DrAttai #BCSM @lobular |
| Julie Gralow @jrgralow As always, we need research and evidence to improve outcomes from (and treatments for) breast and all cancers! #bcsm https://t.co/W1pMEcxJsU |
| Dr. Kelly Shanahan @stage4kelly @jrgralow I wonder if this is something else that the @MBC_Project should look at? @Nikhilwagle ? @corrie_painter ? #bcsm |
| The IBC Network Foundation @TalkIBC RT @jrgralow: As always, we need research and evidence to improve outcomes from (and treatments for) breast and all cancers! #bcsm https://t.co/W1pMEcxJsU |
| Matthew J. Sikora, PhD @mjsikora RT @oesterreichs: #BCSM T3 - research on ILC has been limited in the past at least in part due to limited availability of ILC models. We have made some recent progress, see: https://t.co/5DIbWgNzFv @mjsikora is doing excellent work in this area |
| Lobular Breast Cancer Alliance @LobularBCA @stales PELOPS trial ILC Inclusive https://t.co/IbgNLwnfgU #bcsm #lobular |
| Dr. Steffi Oesterreich @oesterreichs RT @Adrianvlee: Nice clinical review on ILC https://t.co/1M57BSLsnh #BCSM |
| Lex @Lex_in_CO RT @jrgralow: As always, we need research and evidence to improve outcomes from (and treatments for) breast and all cancers! #bcsm https://t.co/W1pMEcxJsU |
| Adrian Lee @Adrianvlee RT @oesterreichs: #BCSM T3 - research on ILC has been limited in the past at least in part due to limited availability of ILC models. We have made some recent progress, see: https://t.co/5DIbWgNzFv @mjsikora is doing excellent work in this area |
| Dr. Steffi Oesterreich @oesterreichs RT @Adrianvlee: @DrHedrick @stales @double_whammied @oesterreichs @LobularBCA @jrgralow Reis-Filho and King doing great work in this area showing that "LCIS is a clonal neoplastic lesion, and provides additional evidence that at least some LCIS are non-obligate precursors of ILC" #BCSM https://t.co/vjCUbiGHtQ |
| Elizabeth Viggiano @EV11PDX Also need non-RECIST eligibility criteria...ROLO and GELATO need RECIST; so many metastatic lobular are with our measurable lesions #bcsm |
| Double Whammy @double_whammied Thank you to @oesterreichs @mjsikora @Prof_Riggins @jrgralow and so many others for the great #lobular work! #BCSM |
| Iman Mohamed @ImmohMD @DrAttai Amen to that ! Surveillance and medications are important but a healthy life style (healthy weight, exercise and lower alcohol consumption) are just as important. #bcsm |
| Howard Karpoff @doctorkarpoff RT @oesterreichs: #BCSM T3 - research on ILC has been limited in the past at least in part due to limited availability of ILC models. We have made some recent progress, see: https://t.co/5DIbWgNzFv @mjsikora is doing excellent work in this area |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @mjsikora @MjoconorMary @double_whammied Yes! Ecad/p120 is the very first test for any new #lobular model #bcsm |
| Dennis Keim @denniskeim RT @paspears88: Lots of great links shared tonight...learning so much about #lobularbreastcancer. Definitely feel like there is a lot to learn through more research in diagnosis, treatment and managing #LBC . Thank you @oesterreichs @jrgralow @Adrianvlee @double_whammied #bcsm |
| IBC Research Fdn @IBCResearch RT @Adrianvlee: @double_whammied Our recent paper showing loss of E-cadherin (CDH1) in ILC results in increased growth factor (IGF) signaling - a potential new therapeutic target #BCSM https://t.co/xxgyoVPml6 |
| Double Whammy @double_whammied RT @jrgralow: As always, we need research and evidence to improve outcomes from (and treatments for) breast and all cancers! #bcsm https://t.co/W1pMEcxJsU |
| Dr. Steffi Oesterreich @oesterreichs RT @Adrianvlee: @double_whammied Our recent paper showing loss of E-cadherin (CDH1) in ILC results in increased growth factor (IGF) signaling - a potential new therapeutic target #BCSM https://t.co/xxgyoVPml6 |
| Dennis Keim @denniskeim RT @oesterreichs: #BCSM T3 - research on ILC has been limited in the past at least in part due to limited availability of ILC models. We have made some recent progress, see: https://t.co/5DIbWgNzFv @mjsikora is doing excellent work in this area |
| The IBC Network Foundation @TalkIBC @double_whammied @oesterreichs @mjsikora @Prof_Riggins @jrgralow Agreed! I learned a lot and will share. #bcsm |
| Dr. Kelly Shanahan @stage4kelly RT @double_whammied: Thank you to @oesterreichs @mjsikora @Prof_Riggins @jrgralow and so many others for the great #lobular work! #BCSM |
| Lobular Breast Cancer Alliance @LobularBCA @stales Endocrine Therapy Trials ILC specific - which is best for ILC? Super important trial #bcsm https://t.co/hb3ymSYd9Q |
| Double Whammy @double_whammied More info about our fabulous #lobular #breastcancer researchers. #BCSM. https://t.co/gY4Bu5GEff |
| Matthew J. Sikora, PhD @mjsikora RT @double_whammied: More info about our fabulous #lobular #breastcancer researchers. #BCSM. https://t.co/gY4Bu5GEff |
| flora migyanka @maggiemoo09 RT @double_whammied: This is excellent information, @DrAttai #BCSM @lobular |
 | Fred Hutchinson Cancer Center @fredhutch RT @jrgralow: As always, we need research and evidence to improve outcomes from (and treatments for) breast and all cancers! #bcsm https://t.co/W1pMEcxJsU |
| Mary O'Connor @MjoconorMary @mjsikora @Prof_Riggins @double_whammied #bcsm is the cell type involved in lobular bc we’ll defined? |
| Julie Gralow @jrgralow Not sure if these links with info on lobular have been shared yet tonight - from @breastcancerorg and @LivingBeyondBC https://t.co/okg1DUga69 https://t.co/V2suZpHjFY #bcsm |
| Double Whammy @double_whammied Read more about @mjsikora's #lobular #breastcancer research here: https://t.co/QMgft06SKi #BCSM |
| Double Whammy @double_whammied RT @jrgralow: Not sure if these links with info on lobular have been shared yet tonight - from @breastcancerorg and @LivingBeyondBC https://t.co/okg1DUga69 https://t.co/V2suZpHjFY #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA Re-evaluate inclusion criteria for ILC metastatic trials #bcsm |
| Alicia C. Staley @stales Wow - fast chat tonight! #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @double_whammied: Read more about @mjsikora's #lobular #breastcancer research here: Read more about @mjsikora's #lobular #breastcancer research here: https://t.co/QMgft06SKi #BCSM |
| IBC Research Fdn @IBCResearch RT @jrgralow: Not sure if these links with info on lobular have been shared yet tonight - from @breastcancerorg and @LivingBeyondBC https://t.co/okg1DUga69 https://t.co/V2suZpHjFY #bcsm |
| Double Whammy @double_whammied Lots of links and info on #lobular #breastcancer at here: https://t.co/0jknBcf39P #BCSM |
| The IBC Network Foundation @TalkIBC RT @double_whammied: Lots of links and info on #lobular #breastcancer at here: Lots of links and info on #lobular #breastcancer at here: https://t.co/0jknBcf39P #BCSM |
| Alicia C. Staley @stales Only 5 minutes left.... Final thoughts for tonight? What have you learned? What will you share with you communities? #bcsm |
| Matthew J. Sikora, PhD @mjsikora More detail about our #lobular work is at https://t.co/x8yl9ofMQX #bcsm |
| Alicia C. Staley @stales RT @double_whammied Lots of links and info on #lobular #breastcancer at here: https://t.co/6pyxqfzMhX #BCSM |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @double_whammied: Lots of links and info on #lobular #breastcancer at here: Lots of links and info on #lobular #breastcancer at here: https://t.co/0jknBcf39P #BCSM |
 | Daniel Stover, MD, FASCO @StoverLab @double_whammied Another pre-surgery trial PELOPS, led by @Otto_DFCI. Kudos to those running trials focusing on #lobular. #bcsm https://t.co/XwyWZwRN4h |
| Gary L. Thompson @garyleethompson @stales Yeah... that was a quick 60 minutes... lots of deep knowledge. The #lobmob team was super prepared!! Thank you. #bcsm |
| Alicia C. Staley @stales ------ please share ------ RT @mjsikora More detail about our #lobular work is at https://t.co/NvzNl7PAtT #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA @jrgralow @Breastcancerorg @LivingBeyondBC https://t.co/leLzt5mvu5 #bcsm |
| Dennis Keim @denniskeim RT @mjsikora: More detail about our #lobular work is at https://t.co/x8yl9ofMQX #bcsm |
| Mary O'Connor @MjoconorMary @double_whammied @oesterreichs @mjsikora @Prof_Riggins @jrgralow #bcsm and so say all of us! |
| Alicia C. Staley @stales RT @LobularBCA @jrgralow @Breastcancerorg @LivingBeyondBC https://t.co/YGQ3AUK7pz #bcsm |
| Dennis Keim @denniskeim RT @double_whammied: Lots of links and info on #lobular #breastcancer at here: Lots of links and info on #lobular #breastcancer at here: https://t.co/0jknBcf39P #BCSM |
| Double Whammy @double_whammied There's also a big #lobular #breastcancer focus at the #NWMBC18 conf coming up in October. More info here: https://t.co/foX4XfMwtw #BCSM |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @mjsikora: More detail about our #lobular work is at https://t.co/x8yl9ofMQX #bcsm |
| Alicia C. Staley @stales The #LobMob is legit! thanks for sharing so much with #BCSM tonight |
| Matthew J. Sikora, PhD @mjsikora @MjoconorMary @Prof_Riggins @double_whammied #bcsm No, it's not. The name 'lobular' implies that it comes from the mammary gland lobules, rather than the ducts, but it's only called that as a historical artifact of its first identification. |
| Jamie Holloway, PhD @jamienholloway Final thoughts: Super important for lobular patients to participate in clinical research so we have more data to help pts make better treatment decisions #bcsm |
| Dr. Kelly Shanahan @stage4kelly #bcsm thank you to all for the opportunity to learn about lobular bc |
| Dr. Steffi Oesterreich @oesterreichs #BCSM Read more about our ongoing trial here https://t.co/0Rda75BGrm |
| Double Whammy @double_whammied Woo hoo! We're legit! #LOBMOB #LOBULAR #BREASTCANCER Thank you so much for hosting us #BCSM! |
| Alicia C. Staley @stales RT @double_whammied big #lobular #breastcancer focus at the #NWMBC18 conf in October. https://t.co/7UpjTx8OiR #BCSM |
| Dennis Keim @denniskeim Wow! What an informative hour! Thanks for everyone who participated. I learned a lot. Have a super week! #bcsm |
| Julie Gralow @jrgralow Great work @lobularbca and @bcsmchat #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA @stales Thank you for hosting #lobmob #lobular #bcsm! We are just getting started! |
| Dr. Kelly Shanahan @stage4kelly I’ll be there! I’m looking forward to learning more about lobular. #bcsm |
 | Dr Samer Al-Bothaigi @SalemSamer RT @jrgralow: As always, we need research and evidence to improve outcomes from (and treatments for) breast and all cancers! #bcsm https://t.co/W1pMEcxJsU |
| Double Whammy @double_whammied RT @StoverLab: @double_whammied Another pre-surgery trial PELOPS, led by @Otto_DFCI. Kudos to those running trials focusing on #lobular. #bcsm https://t.co/XwyWZwRN4h |
| Double Whammy @double_whammied RT @stage4kelly: I’ll be there! I’m looking forward to learning more about lobular. #bcsm |
| Matthew J. Sikora, PhD @mjsikora RT @oesterreichs: #BCSM Read more about our ongoing trial here https://t.co/0Rda75BGrm |
| Double Whammy @double_whammied RT @jamienholloway: Final thoughts: Final thoughts: Super important for lobular patients to participate in clinical research so we have more data to help pts make better treatment decisions #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins This x100 #bcsm |
| Double Whammy @double_whammied RT @Prof_Riggins: This x100 #bcsm |
| Dr. Kelly Shanahan @stage4kelly What she said! I pine for the day when every patient is offered the opportunity to participate in a clinical trial, and that logistics to not preclude most of us from doing so.#bcsm |
| Daniel Stover, MD, FASCO @StoverLab @ndenduluri1 @double_whammied @jrgralow As you pointed out about SOFT/TEXT & little data regarding subsets of large clinical trials...there has also been no report of lobular vs. ductal in TAILORx, which could guide chemo benefit #bcsm |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @stage4kelly: What she said! I pine for the day when every patient is offered the opportunity to participate in a clinical trial, and that logistics to not preclude most of us from doing so.#bcsm |
| Double Whammy @double_whammied Thank you so much to our #lobular researchers and clinicians for joining us for our first #lobular tweetchat tonight. #BCSM #FUcancer |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @jamienholloway: Final thoughts: Final thoughts: Super important for lobular patients to participate in clinical research so we have more data to help pts make better treatment decisions #bcsm |
| Mary O'Connor @MjoconorMary @mjsikora @Prof_Riggins @double_whammied #bcsm this really needs to be pinned down seems basic! |
| Alicia C. Staley @stales Thank you very much for being on tonight's chat: @double_whammied @oesterreichs @LobularBCA @jrgralow We learned so much! #bcsm |
| Lobular Breast Cancer Alliance @LobularBCA Important endocrine therapy trial for #lobular #bcsm Multicenter - |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins And I say this with sensitivity to the issues brought up earlier re. RECIST #bcsm |
| Double Whammy @double_whammied RT @StoverLab: @ndenduluri1 @double_whammied @jrgralow As you pointed out about SOFT/TEXT & little data regarding subsets of large clinical trials...there has also been no report of lobular vs. ductal in TAILORx, which could guide chemo benefit #bcsm |
| IBC Research Fdn @IBCResearch Yeah, what she said! Lots of great info. Thanks everyone & have a great week!! #bcsm |
| Double Whammy @double_whammied RT @stales: Thank you very much for being on tonight's chat: Thank you very much for being on tonight's chat: @double_whammied @oesterreichs @LobularBCA @jrgralow We learned so much! #bcsm |
| Double Whammy @double_whammied RT @denniskeim: Wow! What an informative hour! Thanks for everyone who participated. I learned a lot. Have a super week! #bcsm |
| Dennis Keim @denniskeim RT @jamienholloway: Final thoughts: Final thoughts: Super important for lobular patients to participate in clinical research so we have more data to help pts make better treatment decisions #bcsm |
| Alicia C. Staley @stales @IBCResearch Thanks for joining in! #bcsm |
| Double Whammy @double_whammied RT @oesterreichs: #BCSM Read more about our ongoing trial here https://t.co/0Rda75BGrm |
| Dennis Keim @denniskeim RT @stales: The #LobMob is legit! thanks for sharing so much with #BCSM tonight |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow Some of the PALOMA trials similarly have not published #lobular subgroup analyses. We need these #bcsm |
| Dr. Kelly Shanahan @stage4kelly Have a great week everyone! I’m going to try to get some sleep now that I know that my daughter made it to her hostel in Innsbruck and Willen meeting a friend for the rest of her pre Semester at Sea travels. #bcsm |
| Dr. Steffi Oesterreich @oesterreichs Thanks for joining us at #BCSM. A special thank you to @LobularBCA for their outstanding work in raising awareness and building partnerships between the patient and science community. It's inspiring to work with the #lobmob ! |
| Mary O'Connor @MjoconorMary @StoverLab @ndenduluri1 @double_whammied @jrgralow #bcsm see also this trial for premenopausal https://t.co/FNLAeHBkbT |
| Alicia C. Staley @stales Good night everyone! Thank you! #bcsm |
| Alicia C. Staley @stales @oesterreichs @LobularBCA Great work! #bcsm |
| Julie Gralow @jrgralow Retrospective data from SWOG S8814 showed predictive value for 21-gene recurrence score even in up to 9+ nodes (of course this was mostly ductal). We were restricted in prospective S1207 trial to 1-3 nodes by study sponsors/approvers, not the data. #bcsm |
| Dennis Keim @denniskeim RT @double_whammied: Thank you so much to our #lobular researchers and clinicians for joining us for our first #lobular tweetchat tonight. #BCSM #FUcancer |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @oesterreichs: #BCSM Read more about our ongoing trial here https://t.co/0Rda75BGrm |
| Julie Gralow @jrgralow RT @StoverLab: @ndenduluri1 @double_whammied @jrgralow As you pointed out about SOFT/TEXT & little data regarding subsets of large clinical trials...there has also been no report of lobular vs. ductal in TAILORx, which could guide chemo benefit #bcsm |
| Alicia C. Staley @stales @double_whammied thanks for rallying the #LobMob #bcsm |
| Double Whammy @double_whammied Oh brother. Seriously? Maybe we should just start calling it #globular then. #BCSM |
| Matthew J. Sikora, PhD @mjsikora Wow, that was an intense first live BCSM for me! Thanks #BCSM for hosting the #lobmob and talking about #lobular breast cancer. Always happy to chat off-hour about what we're doing to learn more about ILC. |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins RT @mjsikora: Wow, that was an intense first live BCSM for me! Thanks #BCSM for hosting the #lobmob and talking about #lobular breast cancer. Always happy to chat off-hour about what we're doing to learn more about ILC. |
| Alicia C. Staley @stales Good night #BCSM crew. Have a great week. If you need anything, send out a tweet to #BCSM. The bat signal is always on |
| Double Whammy @double_whammied You are a rock star, Matthew! Thank you so much for all that you do for the #lobmob! #BCSM |
| Gary L. Thompson @garyleethompson Quick little plug for @LPseattle neighbor, my sister-in-law, @LobularBCA web designer and Suzanne Harrison Homes. Super creative! Her sister, my Maureen, passed of #mbc on 10.21.2014. https://t.co/TBMBXxaAjH #bcsm has heart!! https://t.co/l1iq1le98A |
| Dennis Keim @denniskeim RT @stales: Good night #BCSM crew. Have a great week. If you need anything, send out a tweet to #BCSM. The bat signal is always on |
| Alicia C. Staley @stales RT @DrAttai #bcsm #bccww #gyncsm Tuesday 8/14 - @Sharsheret (free!) webinar on breast and ovarian cancer trial highlights from… https://t.co/nyfUIjLFWH |
| Matthew J. Sikora, PhD @mjsikora @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow We need angry advocates at our funding agencies to insist that ILC must be accounted for when trials are designed! #bcsm |
| Dennis Keim @denniskeim RT @mjsikora: Wow, that was an intense first live BCSM for me! Thanks #BCSM for hosting the #lobmob and talking about #lobular breast cancer. Always happy to chat off-hour about what we're doing to learn more about ILC. |
| Howard Karpoff @doctorkarpoff RT @stales: RT @DrAttai #bcsm #bccww #gyncsm Tuesday 8/14 - @Sharsheret (free!) webinar on breast and ovarian cancer trial highlights from… https://t.co/nyfUIjLFWH |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins Goodnight everyone! What a great chat! #bcsm |
| Double Whammy @double_whammied Angry advocates R us! ; ) #BCSM |
| Julie Gralow @jrgralow Would like to see the data. Suspect a lot of lobulars had low 21-gene RS (many < 11 even). #bcsm https://t.co/uUIao9rdTO |
| Double Whammy @double_whammied RT @Prof_Riggins: Goodnight everyone! What a great chat! #bcsm |
| Double Whammy @double_whammied RT @stales: RT @DrAttai #bcsm #bccww #gyncsm Tuesday 8/14 - @Sharsheret (free!) webinar on breast and ovarian cancer trial highlights from… https://t.co/nyfUIjLFWH |
| Double Whammy @double_whammied RT @stales: Good night #BCSM crew. Have a great week. If you need anything, send out a tweet to #BCSM. The bat signal is always on |
| Double Whammy @double_whammied RT @jrgralow: Would like to see the data. Suspect a lot of lobulars had low 21-gene RS (many < 11 even). #bcsm https://t.co/uUIao9rdTO |
| Double Whammy @double_whammied RT @ndenduluri1: |
| Double Whammy @double_whammied RT @mjsikora: @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow We need angry advocates at our funding agencies to insist that ILC must be accounted for when trials are designed! #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @mjsikora @StoverLab @ndenduluri1 @double_whammied @jrgralow Key word being “designed” - and powered #bcsm |
| Alicia C. Staley @stales @double_whammied #bcsm is always here for you! Thank you! |
| Adrian Lee @Adrianvlee Thanks @stales for the #BCSM chat, and to all participants. Fingers aching.... #BCSM #lobmob #globular |
| Lobular Breast Cancer Alliance @LobularBCA @mjsikora @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow We need ILC Research advocates to make sure ILC is included learn more here #bcsm https://t.co/iTwGNXuafu and include ILC in the breast cancer conversation https://t.co/9YvXyt5m4p |
| Double Whammy @double_whammied RT @stage4kelly: Have a great week everyone! I’m going to try to get some sleep now that I know that my daughter made it to her hostel in Innsbruck and Willen meeting a friend for the rest of her pre Semester at Sea travels. #bcsm |
| Matthew J. Sikora, PhD @mjsikora RT @double_whammied: Angry advocates R us! ; ) #BCSM |
| Double Whammy @double_whammied RT @Prof_Riggins: @StoverLab @ndenduluri1 @double_whammied @jrgralow Some of the PALOMA trials similarly have not published #lobular subgroup analyses. We need these #bcsm |
| Julie Gralow @jrgralow Agree, but would caution that central review to confirm lobular status (or at least requirement for e-cadherin staining) would need to be done. I see a lot of path reports that say "mixed ductal/lobular" or "ductal with lobular features" #bcsm https://t.co/KcQnUCLQkk |
| Alicia C. Staley @stales RT @Adrianvlee: Thanks @stales for the #BCSM chat, and to all participants. Fingers aching.... #BCSM #lobmob #globular |
| Alicia C. Staley @stales @Adrianvlee Thanks! It was a fast chat tonight! #BCSM |
 | Susan MacDonald @smacdon932 @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow Do you know if they are planning to? #bcsm |
| Double Whammy @double_whammied RT @stage4kelly: #bcsm thank you to all for the opportunity to learn about lobular bc |
| Matthew J. Sikora, PhD @mjsikora RT @LobularBCA: @mjsikora @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow We need ILC Research advocates to make sure ILC is included learn more here #bcsm https://t.co/iTwGNXuafu and include ILC in the breast cancer conversation https://t.co/9YvXyt5m4p |
| Mary O'Connor @MjoconorMary #Bcsm goodnight and thanks from Kildare Ireland delighted to advocate here |
| Lobular Breast Cancer Alliance @LobularBCA Help us educate and elevate ILC in the breast cancer Conversation #bcsm https://t.co/9YvXyt5m4p |
| Double Whammy @double_whammied Looking forward to reading the transcript of the #lobular #breastcancer #BCSM tweetchat so I can actually see the entire conversation. That was wild! |
| Double Whammy @double_whammied RT @garyleethompson: Quick little plug for @LPseattle neighbor, my sister-in-law, @LobularBCA web designer and Suzanne Harrison Homes. Super creative! Her sister, my Maureen, passed of #mbc on 10.21.2014. https://t.co/TBMBXxaAjH #bcsm has heart!! https://t.co/l1iq1le98A |
| Julie Gralow @jrgralow RT @LobularBCA: @mjsikora @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow We need ILC Research advocates to make sure ILC is included learn more here #bcsm https://t.co/iTwGNXuafu and include ILC in the breast cancer conversation https://t.co/9YvXyt5m4p |
| Double Whammy @double_whammied RT @smacdon932: @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow Do you know if they are planning to? #bcsm |
| Double Whammy @double_whammied RT @jrgralow: Agree, but would caution that central review to confirm lobular status (or at least requirement for e-cadherin staining) would need to be done. I see a lot of path reports that say "mixed ductal/lobular" or "ductal with lobular features" #bcsm https://t.co/KcQnUCLQkk |
| Double Whammy @double_whammied RT @LobularBCA: @mjsikora @Prof_Riggins @StoverLab @ndenduluri1 @double_whammied @jrgralow We need ILC Research advocates to make sure ILC is included learn more here #bcsm https://t.co/iTwGNXuafu and include ILC in the breast cancer conversation https://t.co/9YvXyt5m4p |
| Double Whammy @double_whammied RT @stales: @double_whammied #bcsm is always here for you! Thank you! |
| Double Whammy @double_whammied RT @Prof_Riggins: @mjsikora @StoverLab @ndenduluri1 @double_whammied @jrgralow Key word being “designed” - and powered #bcsm |
| Mary O'Connor @MjoconorMary @ndenduluri1 @StoverLab @double_whammied @jrgralow #bcsm Thanks for that |
| Susan MacDonald @smacdon932 @StoverLab @ndenduluri1 @double_whammied @jrgralow Dr. Sparano of TailorX wants to segment ILC but he said he needs funding to do it. #bcsm |
| Dr. Rebecca B. Riggins 🇻🇮👩🏻🔬⛵️ @Prof_Riggins @jrgralow The Ecad/p120 requirement is essential #bcsm |
| Mary O'Connor @MjoconorMary @smacdon932 @StoverLab @ndenduluri1 @double_whammied @jrgralow #bcsm we’ll get the funding! |
| Double Whammy @double_whammied RT @MjoconorMary: @smacdon932 @StoverLab @ndenduluri1 @double_whammied @jrgralow #bcsm we’ll get the funding! |
| Double Whammy @double_whammied RT @smacdon932: @StoverLab @ndenduluri1 @double_whammied @jrgralow Dr. Sparano of TailorX wants to segment ILC but he said he needs funding to do it. #bcsm |
| Double Whammy @double_whammied RT @Prof_Riggins: @jrgralow The Ecad/p120 requirement is essential #bcsm |
 | HarveyISinger @UVharvey RT @malefitness: A case of a man with LBC: https://t.co/rRFEQLhnSG #bcsm |
 | Wafik S. El-Deiry, MD, PhD, FACP @weldeiry The latest The Cancer Plus Daily! https://t.co/tzBdELECjD Thanks to @DrJohnSuh @mzuppy @dylanlscott #sharedfacts #bcsm |
#BCSM content from Twitter.